<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Biomed Sci</journal-id><journal-id journal-id-type="iso-abbrev">J. Biomed. Sci</journal-id><journal-title-group><journal-title>Journal of Biomedical Science</journal-title></journal-title-group><issn pub-type="ppub">1021-7770</issn><issn pub-type="epub">1423-0127</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6203212</article-id><article-id pub-id-type="publisher-id">475</article-id><article-id pub-id-type="doi">10.1186/s12929-018-0475-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Jaundice revisited: recent advances in the diagnosis and treatment of inherited cholestatic liver diseases</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Chen</surname><given-names>Huey-Ling</given-names></name><address><email>hueyling@ntu.edu.tw</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Shang-Hsin</given-names></name><address><email>shanghsinwu@ntu.edu.tw</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Hsu</surname><given-names>Shu-Hao</given-names></name><address><email>hsush1@ntu.edu.tw</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Liou</surname><given-names>Bang-Yu</given-names></name><address><email>byliou@ntu.edu.tw</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Hui-Ling</given-names></name><address><email>hlchen9@ntu.edu.tw</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Chang</surname><given-names>Mei-Hwei</given-names></name><address><email>changmh@ntu.edu.tw</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0546 0241</institution-id><institution-id institution-id-type="GRID">grid.19188.39</institution-id><institution>Departments of Pediatrics, </institution><institution>National Taiwan University College of Medicine and Children&#8217;s Hospital, </institution></institution-wrap>17F, No. 8, Chung Shan S. Rd, Taipei, 100 Taiwan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0546 0241</institution-id><institution-id institution-id-type="GRID">grid.19188.39</institution-id><institution>Department of Medical Education and Bioethics, </institution><institution>National Taiwan University College of Medicine, </institution></institution-wrap>No. 1, Jen Ai Rd Section 1, Taipei, 100 Taiwan </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0572 7815</institution-id><institution-id institution-id-type="GRID">grid.412094.a</institution-id><institution>Hepatitis Research Center, National Taiwan University Hospital, </institution></institution-wrap>Changde St. No.1, Zhongzhen Dist., Taipei 100, Taiwan </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0546 0241</institution-id><institution-id institution-id-type="GRID">grid.19188.39</institution-id><institution>Graduate Institute of Clinical Medicine, </institution><institution>National Taiwan University College of Medicine, </institution></institution-wrap>No. 7 Chung Shan S. Rd, Taipei 100, Taiwan </aff><aff id="Aff5"><label>5</label>Graduate Institute of Anatomy and Cell Biology, Nationatl Taiwan University College of Medicine, No. 1 Jen Ai Rd Section 1, Taipei 100, Taiwan </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>10</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>10</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>25</volume><elocation-id>75</elocation-id><history><date date-type="received"><day>11</day><month>5</month><year>2018</year></date><date date-type="accepted"><day>3</day><month>10</month><year>2018</year></date></history><permissions><copyright-statement>&#169; The Author(s). 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Jaundice is a common symptom of inherited or acquired liver diseases or a manifestation of diseases involving red blood cell metabolism. Recent progress has elucidated the molecular mechanisms of bile metabolism, hepatocellular transport, bile ductular development, intestinal bile salt reabsorption, and the regulation of bile acids homeostasis.</p></sec><sec><title>Main body</title><p id="Par2">The major genetic diseases causing jaundice involve disturbances of bile flow. The insufficiency of bile salts in the intestines leads to fat malabsorption and fat-soluble vitamin deficiencies. Accumulation of excessive bile acids and aberrant metabolites results in hepatocellular injury and biliary cirrhosis. Progressive familial intrahepatic cholestasis (PFIC) is the prototype of genetic liver diseases manifesting jaundice in early childhood, progressive liver fibrosis/cirrhosis, and failure to thrive. The first three types of PFICs identified (PFIC1, PFIC2, and PFIC3) represent defects in FIC1 (<italic>ATP8B1</italic>), BSEP (<italic>ABCB11</italic>), or MDR3 (<italic>ABCB4</italic>). In the last 5&#160;years, new genetic disorders, such as TJP2, FXR, and MYO5B defects, have been demonstrated to cause a similar PFIC phenotype. Inborn errors of bile acid metabolism also cause progressive cholestatic liver injuries. Prompt differential diagnosis is important because oral primary bile acid replacement may effectively reverse liver failure and restore liver functions. DCDC2 is a newly identified genetic disorder causing neonatal sclerosing cholangitis. Other cholestatic genetic disorders may have extra-hepatic manifestations, such as developmental disorders causing ductal plate malformation (Alagille syndrome, polycystic liver/kidney diseases), mitochondrial hepatopathy, and endocrine or chromosomal disorders. The diagnosis of genetic liver diseases has evolved from direct sequencing of a single gene to panel-based next generation sequencing. Whole exome sequencing and whole genome sequencing have been actively investigated in research and clinical studies. Current treatment modalities include medical treatment (ursodeoxycholic acid, cholic acid or chenodeoxycholic acid), surgery (partial biliary diversion and liver transplantation), symptomatic treatment for pruritus, and nutritional therapy. New drug development based on gene-specific treatments, such as apical sodium-dependent bile acid transporter (ASBT) inhibitor, for BSEP defects are underway.</p></sec><sec><title>Short conclusion</title><p id="Par3">Understanding the complex pathways of jaundice and cholestasis not only enhance insights into liver pathophysiology but also elucidate many causes of genetic liver diseases and promote the development of novel treatments.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Cholestasis</kwd><kwd>Genetic liver disease</kwd><kwd>Pediatric</kwd><kwd>Progressive familial intrahepatic cholestasis</kwd><kwd>Next generation sequencing</kwd><kwd>Bile acids</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; The Author(s) 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par44">Jaundice is a common symptom of inherited or acquired liver diseases of various causes. The underlying biochemical disturbance of jaundice is defined by direct or indirect hyperbilirubinemia. These two categories may represent different mechanisms causing jaundice. Indirect hyperbilirubinemia typically results from increased red blood cell turnover, increased bilirubin loading, or disturbances in hepatocellular update and bilirubin conjugation. Direct hyperbilirubinemia, typically defined as a direct/total bilirubin ratio of more than 15&#8211;20%, or a direct bilirubin level above 1.0&#160;mg/dL, is collectively defined as cholestasis.</p><p id="Par45">Recent progress in the past two decades has largely elucidated the molecular mechanisms underlying bile metabolism (including bilirubin, bile acids, cholesterol, phospholipid, and xenobiotics metabolism), hepatocellular transport (including uptake from sinusoidal blood and export to the canaliculus and bile ducts), bile ductular development, the intestinal reabsorption of bile salts, and the regulation of bile acids and cholesterol homeostasis. The understanding of these complex pathways not only provides insights into liver physiology but also elucidates many causes of genetic liver disease and facilitates the development of novel treatments. This review will focus mainly at hepatobiliary causes of jaundice and inherited cholestasis.</p></sec><sec id="Sec2"><title>Main text</title><sec id="Sec3"><title>The composition and function of bile</title><p id="Par46">The hepatobiliary system comprises the liver, bile duct and gall bladder. Bile is synthesized and secreted by polarized hepatocytes into bile-canaliculi, flows through bile ducts, stored in the gall bladder and is finally drained into the duodenum. The main physiological function of bile is to emulsify the lipid content of food, and this lipid emulsion facilitates lipid digestion and the absorption of lipid-soluble substances. Additionally, bile secretion is an important route to regulate cholesterol homeostasis, hemoglobin catabolism, and the elimination of drugs or drug metabolites [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p id="Par47">Bile is a yellow-to-greenish amalgam of water, bile acids, ions, phospholipids (phosphatidylcholine), cholesterol, bilirubin, proteins (such as glutathione and peptides) and the other xenobiotics [<xref ref-type="bibr" rid="CR1">1</xref>]. The yellow-to-greenish color of bile is caused by bilirubin and its derivative, which are also the origin of stool color. Bilirubin is the end catabolite of hemoglobin and other heme-containing proteins, such as myoglobin. The heme molecule is oxidized to biliverdin in hepatocytes and then reduced to unconjugated bilirubin. Unconjugated bilirubin is conjugated with one to two molecules of glucuronic acid via Uridine 5'-diphospho-glucuronosyltransferase 1A1 (UGT1A1). Bilirubin conjugation increases water solubility and reduces cytotoxicity of bilirubin. Hepatic and intestinal UGT1A1 are functionally reduced in neonatal stages, and hence, unconjugated hyperbilirubinemia is commonly found in human neonates [<xref ref-type="bibr" rid="CR2">2</xref>]. Conjugated bilirubin, or direct bilirubin, is the major form of bilirubin in bile and is eliminated in stool. Jaundice, a yellowish pigmentation of the skin and sclera, is caused by the disrupted excretion of bilirubin and biliverdin. Interestingly, some studies involving neonates or adults have shown that hyperbilirubinemia is protective against diseases, including metabolic syndrome and asthma, [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>] suggesting that bilirubin may play a role as an antioxidant [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par48">Bile acids are colorless and are the most abundant organic components of bile. Bile acids, a group of detergent-like molecules, are synthesized from cholesterol and are typically associated with sodium or potassium ions in the form of bile salts. Bile salts mediate lipid emulsion and act as signaling molecules to regulate gene expression [<xref ref-type="bibr" rid="CR5">5</xref>&#8211;<xref ref-type="bibr" rid="CR7">7</xref>]. Phospholipids and cholesterol, the second and third most abundant organic components of bile, protect against injury of the biliary epithelium from bile acids [<xref ref-type="bibr" rid="CR1">1</xref>].</p></sec><sec id="Sec4"><title>Biosynthesis and enterohepatic circulation of bile acids</title><p id="Par49">Bile acids can be synthesized from cholesterol via two pathways in hepatocytes to generate two primary bile acids, cholic acid (CA) and chenodeoxycholic acid (CDCA), through cytochrome P450 (CYP) enzymes, including CYP7A1, CYP8B1, and CYP27A1. Primary bile acids are conjugated with glycine or taurine (glyco- or tauro-conjugated CA and CDCA), with increased solubility and reduced cytotoxicity. In the intestines, gut-resident microbiota deconjugate bile salts to generate the secondary bile acids, deoxycholic acid (DCA) and lithocholic acid (LCA) [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. In human livers, de novo synthesized bile salts are 500&#8211;600&#160;mg daily [<xref ref-type="bibr" rid="CR10">10</xref>]. More than 90% of bile acids are reabsorbed at the distal ileum and transported back to the liver through circulation systems for the next cycle, called the enterohepatic circulation. Bile salts cycle 6- to 10-times daily. The total amount of bile salt in the body is called bile acid pool, which is approximately 2&#8211;3&#160;g. In contrast to bile acids, only trace amounts of conjugated bilirubin will enter the enterohepatic circulation. The blockage of enterohepatic circulation to enhance bile salt elimination has been applied in surgical and medical treatments for cholestasis (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>The enterohepatic circulation, homeostasis of bile acids and treatment targets for cholestasis. The grey arrows indicate the route of enterohepatic circulation of bile acids. Bile acids are synthesized from cholesterol in hepatocytes to generate the primary bile acids CA and CDCA. After conjugation with glycine or taurine, bile acids (BAs) are transported from hepatocytes into the bile canaliculi via BSEP. Intestinal microbiota converts primary bile acids into the secondary bile acids DCA and LCA. Most of BAs reabsorbed by the enterocytes through ASBT in the apical membrane and then delivered into the portal circulation system via BA efflux transporter OST&#945;/&#946; in the basolateral membrane. BAs are re-absorbed into hepatocytes. Hepatocytes secrete these BAs along with the de novo synthesized bile acids enter the next cycle. Bile acids also play roles in signaling to regulate the homeostasis of bile acids. The nuclear receptor FXR is the bile acid receptor to regulate bile acid homeostasis at the synthesis and the elimination levels, acting in the hepatocytes and enterocytes. The figure also shows different therapeutic targets at hepatocellular transport or enterohepatic circulations. 1&#176;BAs, primary bile acids; 2&#176;BAs, secondary bile acids; 4-PB, 4-phenylbutyrate; ASBT, apical sodium dependent bile acid transporter; BAs, bile acids; BSEP, bile salt export pump; CA, cholic acid; CDCD, chenodeoxy cholic acid; DCA, deoxycholic acid; FGFR4, fibroblast growth factor receptor 4; FXR, farnesoid X receptor; G(T)CA, glyco- or tauro-cholic acid; G(T)CDCA, glyco- or tauro-chenodeoxy cholic acid; LCA, lithocholic acid; MRP3, multidrug resistance-associated protein 3; MRP4, multidrug resistance-associated protein 4; NTCP, sodium/taurocholate co-transporting polypeptide; OATP1B1/3, organic-anion-transporting polypeptide 1B1 and 1B3; OST&#945;/&#946;, organic solute transporter-&#945;/&#946;; RXR&#945;, retinoid X receptor &#945;; SHP, small heterodimer partner; UDCA, ursodeoxycholic acid</p></caption><graphic xlink:href="12929_2018_475_Fig1_HTML" id="MO1"/></fig></p><p id="Par50">In human fetuses after 22 and 26&#160;weeks of gestation, taurine-conjugated di-hydroxyl bile acids can be detected in the gallbladder. After 28&#160;weeks, small amounts of glycine conjugates are synthesized. In postnatal stages, the ratio of CA to CDCA declines from 2.5 to 1.2 [<xref ref-type="bibr" rid="CR11">11</xref>]. Infant livers are under development, have a small bile acid pool, and have a limited capacity for bile excretion and reabsorption. Therefore, neonates and infants, particularly premature infants, are prone to cholestasis caused by various insults, such as ischemia, drugs, infection, or parenteral nutrition.</p></sec><sec id="Sec5"><title>Hepatocellular transporters mediating bile flow (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>)</title><p id="Par51">Bile flow is generated by osmotic forces associated with the amount of bile salts secreted into bile canaliculi. Bile secretion from hepatocytes is mediated by a group of transport proteins, particularly ATP-binding cassette (ABC) containing proteins. The bile salt export pump (BSEP encoded by <italic>ABCB11</italic>) is the pivotal transporter mediating bile acid transport into bile canaliculi. BSEP is exclusively expressed in the apical/canalicular membrane of hepatocytes. After secreted into the small intestine, bile salts are absorbed into intestinal cells via the apical sodium-dependent bile acid transporter (ASBT encoded by <italic>SLC10A2</italic>) and then secreted into the circulation system through the basolateral heterodimeric transporter OST&#945;-OST&#946; (encoded by <italic>OSTA</italic> and <italic>OSTB</italic>, respectively) [<xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR14">14</xref>].<fig id="Fig2"><label>Fig. 2</label><caption><p>Hepatocellular transporters, enzymes, and regulators involving in bile transport, metabolism, and secretion. A1AD, alpha-1 antitrypsin deficiency; A1AT, alpha-1 antitrypsin; ALG, Alagille syndrome; BAs, bile acids; BSEP, bile salt export pump; Canalicular, canalicular membrane; CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; DJ, Dubin-Johnson syndrome; FIC1, familial intrahepatic cholestasis 1; FXR, farnesoid X receptor; JAG1, jagged 1; MDR3, multidrug resistance protein 3; MRP2, multidrug resistance-associated protein 2; MRP3, multidrug resistance-associated protein 3; MRP4, multidrug resistance-associated protein 4; MYO5B, myosin VB; NTCP, sodium/taurocholate co-transporting polypeptide; OATP1B1, organic-anion-transporting polypeptide 1B1; OATP1B3, organic-anion-transporting polypeptide 1B3; OST&#945;/&#946;, organic solute transporter-&#945;/&#946;; PC, phosphatidylcholine; PFIC, progressive familial intrahepatic cholestasis; PS, phosphatidylserine; Sinusoidal, sinusoidal membrane; SHP, small heterodimer partner; TJP2, tight junction protein 2</p></caption><graphic xlink:href="12929_2018_475_Fig2_HTML" id="MO2"/></fig></p><p id="Par52">The basolateral/sinusoidal membrane of hepatocytes contains several bile acid transporters to absorb bile acids from sinusoidal blood, including Na<sup>+</sup>-taurocholate co-transporting polypeptide NTCP (encoded by <italic>SLC10A1</italic>), OATP1B1 and OATP1B3 (encoded by <italic>SLCO1B1</italic> and <italic>SLCO1B3</italic>, respectively) [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. OATP1B1 and OATP1B3 also function in the uptake of bilirubin into hepatocytes [<xref ref-type="bibr" rid="CR16">16</xref>]. Conjugated bilirubin and organic anions are transported via canalicular multidrug resistance-associated protein 2 MRP2 (encoded by <italic>ABCC2</italic>) and, to a lesser extent, via ABCG2 into bile. Under physiological or cholestatic conditions, conjugated bilirubin may be excreted via MRP3 (encoded by <italic>ABCC3</italic>) across sinusoidal membranes into blood, to a lesser extent, and reabsorbed by OATP1B1 and OATP1B3 [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par53">Lipids are also important components of bile. The heterodimeric transporter ABCG5/8 mediates cholesterol across canalicular membranes. Phosphatidylcholine (PC) is flopped by the floppase multidrug resistance P-glycoprotein 3 (MDR3, encoded by <italic>ABCB4</italic>) to the outer lipid leaflet and then extracted by bile salts into bile to form micelles. The combination of cholesterol and sphingomyelin makes membranes highly detergent resistant [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. The flippase FIC1(<italic>ATP8B1</italic>) is required to flip phosphatidylserine (PS) back from the outer lipid leaflet to the inner lipid leaflet of the canalicular membrane to stabilize the integrity of the canalicular membrane [<xref ref-type="bibr" rid="CR19">19</xref>]. Additionally, FIC1 is required for the functional expression of MDR3 [<xref ref-type="bibr" rid="CR20">20</xref>]. Thus, hepatocytes and biliary epithelium are protected from bile acid toxicity through the efflux of bile acids mediated by BSEP and the functions of MDR3 and FIC1.</p></sec><sec id="Sec6"><title>Homeostasis of bile acid pools</title><p id="Par54">The homeostasis of bile acids is tightly controlled by the de novo synthesis of bile acids and the expression of transporters that affect hepatocellular bile acid levels. The key regulating molecules are farnesoid X receptor (FXR, <italic>NR1H4</italic>) and membrane-bound Takeda G protein-coupled receptor (TGR5) [<xref ref-type="bibr" rid="CR6">6</xref>]. FXR is a nuclear receptor that is highly expressed in hepatocytes and enterocytes in the distal small intestine and colon. TGR5 is expressed in enteroendocrine cells, gallbladder cells and cholangiocytes. FXR forms heterodimers with other nuclear receptors to mediate its transcriptional activity [<xref ref-type="bibr" rid="CR21">21</xref>&#8211;<xref ref-type="bibr" rid="CR24">24</xref>]. Upon binding with bile acids as its natural ligands, FXR downregulates the expression of bile acid synthesis enzymes (mainly CYP7A1) and the sinusoidal uptake transporter of NTCP but upregulates the expression of the bile acid efflux transporter BSEP to reduce intracellular bile acid concentrations [<xref ref-type="bibr" rid="CR25">25</xref>&#8211;<xref ref-type="bibr" rid="CR29">29</xref>]. When bile acids are accumulated in hepatocytes, activated hepatic FXR increases sinusoidal bile acid efflux via MRP4 and heterodimeric OST&#945;/&#946; [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. FXR also inhibits the expression of the ileal bile acid transporter ASBT to reduce the enterohepatic circulation of bile acids [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Activation of FXR induces enterocytes to release FGF19. Through enterohepatic circulation via the portal vein, FGF19 translocates to the liver and inhibits the expression of CYP7A1 in the hepatocytes [<xref ref-type="bibr" rid="CR34">34</xref>]. Through FXR, bile is controlled via a negative feedback loop at the transcriptional level via transporters and bile acid synthesis systems.</p></sec><sec id="Sec7"><title>Cholestasis</title><p id="Par55">Cholestasis is defined as disturbances in bile flow caused by diseases either in the hepatocytes, intrahepatic bile ducts or extrahepatic biliary system. Cholestatic liver disease is one of the most common forms of liver disorders resulting from inherited or acquired liver diseases. Inadequate bile flow of any causes results in accumulation of bile contents, including bilirubin, bile acids, and lipids in the liver, and consequently cause elevated levels of bilirubin and bile salts in the liver and blood, as well as dysregulated lipid metabolisms. Clinically, patients usually manifest jaundice as a result of hyperbilirubinemia. Other symptoms include clay stool, pruritus, or infrequently, bleeding episodes such as intracranial hemorrhage. Chronic cholestatic liver disease may progress to liver cirrhosis and liver failure and is the leading cause of pediatric liver transplantation. According to the anatomical location of its occurrence, cholestasis is divided into extrahepatic and intrahepatic cholestasis. Extrahepatic cholestasis is caused by structural abnormalities of the biliary tract including the obstruction of bile ducts and the gallbladder. Surgical treatments are typically applied to restore the physiological function. However, intrahepatic cholestasis is more complicated and typically requires sophisticated investigations. The common causes of extrahepatic and intrahepatic cholestasis are shown in Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>.<fig id="Fig3"><label>Fig. 3</label><caption><p>Etiologies of intrahepatic and extrahepatic cholestasis of inherited or secondary causes. dis: disorders</p></caption><graphic xlink:href="12929_2018_475_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec8"><title>Etiologies of inherited bilirubin metabolism disorders causing indirect hyperbilirubinemia</title><p id="Par56">Disturbances in the bilirubin metabolisms result in accumulation of bilirubin in the liver and blood, and consequently cause hyperbilirubinemia detected by routine serum biochemistry test, or called jaundice clinically. Gilbert syndrome is a benign clinical condition usually present mild intermittent jaundice in children or adult. TA repeat polymorphism (UGT1A1*28) in the promoter of UGT1A1 gene is the most commonly affected region. Gilbert syndrome can be identified in the general population, and many are identified by blood test of a health exam [<xref ref-type="bibr" rid="CR35">35</xref>].</p><p id="Par57">Crigler-Najjar syndrome is also cause by mutations in the <italic>UGT1A1</italic> gene. Type I is a rare autosomal recessive disorder with complete loss of enzymatic function that cause extremely high bilirubin levels (above 20&#160;mg/dL) and may lead to encephalopathy due to kernicterus. Treatments include phototherapy, exchange transfusion, or liver transplantation. Crigler-Najjar syndrome Type II manifests medium levels of hyperbilirubinemia (around 5&#8211;20&#160;mg/dL), with retention of some enzymatic activity. Phenobarbital can be used intermittently to reduce bilirubin levels below 10-15&#160;mg/dL.</p><p id="Par58">Genetic variations in the <italic>UGT1A1</italic> gene, especially 211&#160;G to A (G71R in exon 1) mutation, as well as variations in the glucose-6-phosphate dehydrogenase (<italic>G6PD</italic>) and <italic>OATP2</italic> genes, also contribute to the occurrence of neonatal jaundice and breast-feeding jaundice [<xref ref-type="bibr" rid="CR36">36</xref>&#8211;<xref ref-type="bibr" rid="CR38">38</xref>]. Homozygous 211&#160;G to A mutation has been reported to be associated with severe neonatal jaundice.</p></sec><sec id="Sec9"><title>Etiologies of inherited cholestasis causing direct hyperbilirubinemia</title><p id="Par59">Inherited cholestatic liver diseases may manifest early in life. The presenting age ranges from infancy to young adulthood. In the last 20&#160;years, there has been tremendous progress in understanding the genetic background of cholestatic liver disease [<xref ref-type="bibr" rid="CR39">39</xref>&#8211;<xref ref-type="bibr" rid="CR43">43</xref>]. Table&#160;<xref rid="Tab1" ref-type="table">1</xref> lists the categories and genes involved in inherited genetic disorders. Up to now, more than 100 inherited diseases are identified to cause cholestatic liver diseases with the initial presentation of jaundice. Some disorders may be associated with congenital anomalies or with multiple organ involvement. We have previously investigated the genetic background of pediatric patients in Taiwan with BSEP, FIC1, MDR3 defects [<xref ref-type="bibr" rid="CR44">44</xref>&#8211;<xref ref-type="bibr" rid="CR47">47</xref>]. We have also reported adaptive changes of hepatocyte transporters associated with obstructive cholestasis in biliary atresia, an important extrahepatic cholestatic liver disease with common symptom of prolonged neonatal jaundice [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. The distribution of disease types in Taiwanese infants with intrahepatic cholestatic liver diseases is shown in Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Differential diagnosis of jaundice caused by primary or secondary intrahepatic liver diseases</p></caption></table-wrap><fig id="Fig4"><label>Fig. 4</label><caption><p>Distributions of final diagnosis of intrahepatic cholestasis in infancy in 135 Taiwanese infants 2000&#8211;2012. (Adapted from Lu FT et al., J Pediatr Gastroenterol Nutr 2014;59: 695&#8211;701). ALG, Alagille syndrome; GGT, gamma-glutamyl transpeptidase; IEBAM, inborn error of bile acid metabolism; NH, neonatal hepatitis; NICCD, neonatal intrahepatic cholestasis caused by citrin deficiency; PFIC, progressive familial intrahepatic cholestasis</p></caption><graphic xlink:href="12929_2018_475_Fig4_HTML" id="MO4"/></fig></p><p id="Par60">Progressive familial intrahepatic cholestasis (PFIC) is a clinical syndrome with features of chronic intrahepatic cholestasis that typically begin in infancy and progress to biliary cirrhosis and hepatic failure by the first or second decade of life [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. The first three types of genetic defects identified are commonly referred to as PFIC1, PFIC2, and PFIC3. PFIC1 and PFIC2 are characterized by low serum &#947;-glutamyltransferase (GGT) levels. PFIC1 (Byler&#8217;s disease) patients have FIC1 gene mutations, and PFIC2 patients have mutated BSEP gene. PFIC3 is characterized by high serum GGT levels and is caused by genetic mutations in the MDR3 gene [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. BSEP plays a pivotal role in bile physiology as it mediates canalicular bile salt export and is the main driving force of bile flow [<xref ref-type="bibr" rid="CR53">53</xref>].</p><p id="Par61">With the advances in genetic technologies in recent years, novel disease-causing genes for PFIC have been reported. FXR, the key regulator of bile acid metabolism, have been implicated in a novel form of infant cholestasis with liver failure in two European families [<xref ref-type="bibr" rid="CR54">54</xref>]. We also identified a fatal case of infant cholestasis with liver failure occurring before 3&#160;months of age [<xref ref-type="bibr" rid="CR55">55</xref>]. Additionally, TJP2 and MYO5B have been found to cause PFIC. TJP2 is an important component of tight junctions, and a deficiency of TJP2 disrupts the tight-junction structure in the liver [<xref ref-type="bibr" rid="CR56">56</xref>]. MYO5B is associated with low GGT infant cholestasis. MYO5B is an actin-based motor protein and an effector of Rab11a/b. MYO5B mutations result in the dysregulation of Rab proteins and further disrupt the trafficking of BSEP [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]. Doublecortin domain containing 2 (DCDC2), a tubulin-binding protein, is associated with renal-hepatic ciliopathy and neonatal sclerosing cholangitis [<xref ref-type="bibr" rid="CR59">59</xref>&#8211;<xref ref-type="bibr" rid="CR61">61</xref>]. The mitochondrial transcription factor TFAM is associated with mitochondrial DNA depletion syndrome [<xref ref-type="bibr" rid="CR62">62</xref>]. Recently, a homozygous single nucleotide deletion in organic solute transporter-&#946; (OST&#946;/SLC51B) was demonstrated to cause congenital diarrhea and cholestasis [<xref ref-type="bibr" rid="CR63">63</xref>].</p><p id="Par62">Dubin-Johnson and Rotor syndrome are two inherited disorders manifesting direct hyperbilirubinemia but with normal or minimally elevated alanine transaminase (ALT) levels, clinically manifesting as jaundice. Dubin-Johnson syndrome is caused by disruption of MRP2 and characterized by grossly black livers and pigment deposition in hepatocytes. Neonatal cholestasis caused by Dubin-Johnson syndrome has been reported in Taiwan and Japan [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]. Our group has identified patients recovered from neonatal cholestasis had re-emergence of jaundice in young adulthood after long-term follow-up [<xref ref-type="bibr" rid="CR64">64</xref>]. Rotor syndrome has recently been identified to be caused by genetic disruption of both <italic>SLCO1B1</italic> and <italic>SLCO1B3</italic> genes [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]. These two disorders are benign and do not require specific treatment.</p><p id="Par63">Genetic cholestasis not only causes pediatric liver disease but may also be present in adult liver disease. Additionally, adult liver diseases may result from genetic liver diseases. In general, protein functional disturbances are less detrimental and are typically caused by missense genetic mutations or multifactorial disorders. Cholestasis in pregnancy has been associated with genetic variants/mutations in <italic>ABCB4</italic>, <italic>ABCB11</italic>, <italic>ATP8B1</italic>, <italic>ABCC2</italic> and <italic>TJP2</italic> [<xref ref-type="bibr" rid="CR68">68</xref>]. Adult benign recurrent intrahepatic cholestasis (BRIC) is also associated with PFIC-related genes and may have mutations that are less damaging [<xref ref-type="bibr" rid="CR69">69</xref>&#8211;<xref ref-type="bibr" rid="CR72">72</xref>]. Acquired forms of cholestasis, such as drug-induced liver disease, have also been associated with genetic variants [<xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR74">74</xref>].</p><p id="Par64">Diseases related to ductal plate malformation are an important group of developmental disorders that lead to a paucity or malformation of intrahepatic or interlobular bile ducts. Alagille syndrome, first described by Alagille et al., is based on clinical diagnostic criteria including a characteristic face; a paucity of interlobular bile ducts in liver pathology; and cardiac, eye, and vertebral anomalies [<xref ref-type="bibr" rid="CR75">75</xref>]. The <italic>JAG1</italic> mutation accounts for &gt;&#8201;90% of cases of Alagille syndrome, and mutations in <italic>NOTCH2</italic> have been described in a minority of patients [<xref ref-type="bibr" rid="CR76">76</xref>]. Other syndromic disorders and polycystic liver/kidney diseases may also present with infant cholestasis as the first symptom.</p><p id="Par65">Cholestasis is a common manifestation of hepatic metabolic disorders, including carbohydrate, amino acid, and fat metabolism, as well as mitochondrial and endocrine anomalies. Most of these diseases are rare disorders, and the disease incidence largely depends on ethnic background. For example, neonatal cholestasis caused by citrin deficiency (NICCD) is an important cause of cholestasis in East Asian children [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>]. We have previously identified facial features and biochemical characteristics for the phenotypic diagnosis of NICCD [<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR80">80</xref>]. Alpha 1-antitrypsin (A1AT/SERPINA1) deficiency and cystic fibrosis are important causes in western countries but how lower incidences in Asian populations.</p><p id="Par66">Inborn errors of bile acid metabolism constitute a group of important metabolic disorders causing infant cholestasis. Notably, oral primary bile acid supplementation is effective and can avoid patient deterioration and the need for liver transplantation upon timely treatment [<xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR82">82</xref>].</p><p id="Par67">Neonatal hemochromatosis is an important cause of neonatal liver failure that manifests as early onset cholestasis. However, recent studies have elucidated this condition as a disorder of gestational alloimmune liver diseases instead of hereditary hemochromatosis [<xref ref-type="bibr" rid="CR83">83</xref>]. Treatment involves exchange blood transfusion and intravenous immunoglobulin applied as early as when the neonate is born.</p><p id="Par68">Other congenital anomalies, such as chromosomal anomalies, endocrine disorders, and developmental disorders may also cause cholestasis. Liver disease is typically a multi-organ manifestation of congenital anomalies.</p></sec><sec id="Sec10"><title>Diagnosis</title><sec id="Sec11"><title>Clinical history</title><p id="Par69">A careful clinical history is important to investigate common secondary causes of jaundice and cholestasis, including hemolytic anemia, G6PD deficiency, hereditary spherocytosis and other red cell membrane disorders, prematurity, sepsis, drug-induced liver injury, parenteral nutrition-associated liver diseases, ischemia, and pregnancy. Ethnic background and parental consanguinity are clues for certain types of inherited liver disorders.</p></sec><sec id="Sec12"><title>Phenotypic diagnosis</title><p id="Par70">The traditional phenotypic diagnosis includes low GGT as a signature of PFIC1 (FIC1 defect) and PFIC2 (BSEP defect). GGT levels, Byler&#8217;s bile in electron microscopy, and duodenal biliary bile content can be used as clinical markers to indicate further genetic confirmation [<xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR85">85</xref>]. Syndromic cholestasis, including Alagille syndrome, can be diagnosed by phenotypic criteria [<xref ref-type="bibr" rid="CR75">75</xref>]. Patients with NICCD have phenotypic features, and we have developed a clinical scoring system to aid in diagnosis [<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR86">86</xref>]. Importantly, investigating the involvement of extrahepatic organs is important for differential diagnosis.</p></sec><sec id="Sec13"><title>Biochemical diagnosis</title><p id="Par71">For patients suspecting jaundice or cholestasis, routine liver biochemistry tests include total and direct bilirubin levels, aspartate transferase levels, ALT levels, GGT and alkaline phosphatase (ALP) levels. Low serum GGT level disproportionate to severity of cholestasis is a clinical clue for inherited cholestasis such as PFIC and inborn errors of bile acid synthesis. Some disorders with metabolic signatures can be diagnosed with biochemical analysis. Diseases, such as inborn error of bile acid metabolism (IEBAM), [<xref ref-type="bibr" rid="CR87">87</xref>] and metabolic disorders, such as NICCD, [<xref ref-type="bibr" rid="CR86">86</xref>] require analysis by mass spectrometry.</p></sec><sec id="Sec14"><title>Genetic diagnosis</title><p id="Par72">Genetic diagnosis is a definitive diagnosis for inherited genetic liver diseases, as many of these diseases lack adequate biomarkers. Genetic tests have largely evolved in the past two decades due to the tremendous progress of genetic analysis technologies. Conventional genetic diagnosis uses direct sequencing for selected genes based on the phenotype of the patient. High-throughput methods have subsequently been developed, such as a resequencing chip that detects 5 genes for genetic cholestasis (<italic>SERPINA1</italic>, <italic>JAG1</italic>, <italic>ATP8B1</italic>, <italic>ABCB11</italic>, and <italic>ABCB4</italic>) in 2007 [<xref ref-type="bibr" rid="CR88">88</xref>]. Denaturing high-performance liquid chromatography and high-resolution melting analysis have been used to detect single-gene variants in large numbers of patients [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR79">79</xref>]. Recent next generation sequencing (NGS) panels in liver diseases have incorporated a limited number of genes, particularly PFIC [<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR89">89</xref>]. Expanded panel-based NGS involving more than 50 genes has been used in clinical patients with promising results [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR90">90</xref>]. Whole exome sequencing has been applied to identify novel disease-causing genes [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR63">63</xref>].</p></sec></sec><sec id="Sec15"><title>Treatment</title><sec id="Sec16"><title>Nutritional support</title><p id="Par73">Bile mediates the intestinal absorption of fat and fat-soluble vitamins. In cholestatic liver diseases, the defective absorption of fat and fat-soluble vitamins (vitamins A, D, E, and K) is commonly observed but clinically obscure. Fat malabsorption results in calorie insufficiency and failure to thrive, especially in early childhood. Patients are advised to use formulas containing medium-chain triglycerides or add oils containing medium-chain triglycerides to their food. Deficiency in fat-soluble vitamins may result in multiple organ dysfunctions, including rickets, coagulopathy, and defective neurological, immunological and visual functions. Without supplementation, symptoms of deficiency, such as coagulopathy, osteoporosis, fracture, growth failure and life-threatening hemorrhage, may occur in patients. In addition, deficiencies in fat-soluble vitamins may also cause inadequate anti-oxidation, which is frequently overlooked in clinical patients.</p></sec><sec id="Sec17"><title>Medical treatment</title><p id="Par74">Although jaundice is the common manifestation of the highly variable etiologies, treatment does not target only to jaundice improvement (to reduce serum bilirubin level), but to target the underlying disorders that may cause hepatobiliary injury and progressive fibrosis and cirrhosis, which is usually associated with elevated bile acid levels or abnormal metabolites. Additional treatment goals are to improve nutritional status, pruritus and life quality, to prevent or to treat cirrhosis related complications.</p><p id="Par75">PFICs, Alagille syndrome, and inborn errors of bile acid synthesis are the most devastating disorders that cause cirrhosis and may need liver transplantation. Effective treatment options for PFICs and Alagille syndrome are limited. Several drugs are under investigation and clinical trial. Here we will discuss about the standard treatment and several newly developed therapeutic strategies for these disorders.</p><p id="Par76">Ursodeoxycholic acid (UDCA) has widely been used to treat cholestatic liver disease and is effective to improve biochemical parameters and pruritus [<xref ref-type="bibr" rid="CR91">91</xref>]. However, UDCA is not an ideal therapeutic option for PFIC2 patients with BSEP defects. In animal models, UDCA may aggravate liver injury due to the inability of BSEP to export UDCA from hepatocytes [<xref ref-type="bibr" rid="CR92">92</xref>]. There is a need to develop new drugs targeting BSEP defects. Missense mutations in <italic>BSEP/ABCB11</italic> impair protein translation or intracellular trafficking, which reduce canalicular expression of BSEP and eventually cause cholestasis. Recent studies have indicated that 4-phenylbutyrate (4-PB, Buphenyl), a clinically approved pharmacological chaperone, can be used to restore the canalicular expression of BSEP. By using MDCK II cells and SD rats, Hayashi et al. reported that 4-PB significantly relocalizes and enhances the cell surface expression of both wild-type and mutated rat Bsep [<xref ref-type="bibr" rid="CR93">93</xref>]. Besides its effect on Bsep expression, 4-PB treatment significantly increased hepatic MRP2 and decreased serum bilirubin level in patient with ornithine transcarbamylase deficiency (OTCD) [<xref ref-type="bibr" rid="CR94">94</xref>]. Moreover, Gonzales et al. applied 4-PBA to PFIC2 patients and successfully restored the hepatic secretion of bile acids and decreased total serum bilirubin via the re-localization of mutated BSEP to canalicular membranes [<xref ref-type="bibr" rid="CR95">95</xref>]. In addition to 4-PB, steroids are a therapeutic option to enhance BSEP expression. Cell culture experiments have suggested that dexamethasone upregulates Bsep and Mrp2 at the mRNA level in rat primary hepatocytes [<xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR97">97</xref>], and treatment with glucocorticoids induces the expression of Bsep, Mrp2, and cytochrome P450 oxidase in rat livers [<xref ref-type="bibr" rid="CR98">98</xref>]. Additional animal experiments and clinical tests have shown that steroid treatment improved bile homeostasis. For example, dogs receiving a high dosage of hydrocortisone (5&#160;mg/kg) showed a significant increase in bile flow [<xref ref-type="bibr" rid="CR99">99</xref>]. Engelmann et al. reported that steroids effectively ameliorated cholestatic itches and reduced the serum level of bile salts and bilirubin in two PFIC2 patients carrying missense mutations in BSEP [<xref ref-type="bibr" rid="CR100">100</xref>].</p><p id="Par77">Blocking enterohepatic circulation has been recently shown as a promising strategy to reduce the hepatic accumulation of bile acids in PFIC2 patients. After secretion from the gallbladder into the intestine, a majority of bile acid is absorbed by enterocytes via ASBT and recycled to liver via enterohepatic circulation. Two independent animal studies have shown that small molecule ASBT inhibitors, SC-425 and A4250, effectively reduced the enteric uptake of bile acid, decreased serum total bilirubin levels, and improved liver fibrosis and inflammation in Mdr2 knockout mice, an animal model of PFIC3 [<xref ref-type="bibr" rid="CR101">101</xref>]. Moreover, on March 2018, A4250 successfully passed clinical phase II trials (ClinicalTrials.gov Identifier: NCT02630875).</p><p id="Par78">The recently developed FXR agonist (Obeticholic acid) has been demonstrated to improve the ALP level in primary biliary cirrhosis [<xref ref-type="bibr" rid="CR102">102</xref>], and has also been investigated for the treatment of nonalcoholic steatohepatitis (NASH) [<xref ref-type="bibr" rid="CR103">103</xref>&#8211;<xref ref-type="bibr" rid="CR105">105</xref>].</p><p id="Par79">Certain types of the inborn errors of bile acid metabolism are treatable [<xref ref-type="bibr" rid="CR81">81</xref>]. Oral cholic acid therapy is indicated for 3&#946;-Hydroxy-&#916;(5)-C27-steroid oxidoreductase (HSD3B7) deficiency, &#916; (4)-3-oxosteroid 5&#946;-reductase (SRD5B1, AKR1D1) deficiency, and Zellweger spectrum disorders [<xref ref-type="bibr" rid="CR106">106</xref>]. CDCA has also been reported to be effective for oxysterol 7&#945;-hydroxylase (CYP7B1) deficiency, cerebrotendinous xanthomatosis, and other forms of bile acid synthetic defects [<xref ref-type="bibr" rid="CR107">107</xref>]. After treatment, patients may recover from liver dysfunction, free of jaundice, and avoid liver transplantation. Life-long therapy is indicated for the oral supplementation. Early diagnosis and treatment is important to improve outcome.</p><p id="Par80">Many patients with cholestatic liver disease suffer from pruritus, except patients with inborn errors of bile acid synthesis. Alagille syndrome, PFIC1 and 2 commonly cause disturbing pruritus, which affects daily life quality. Antihistamines, rifampin, and cholestyramine have been used to partially improve the symptoms of this condition. UV-B phototherapy is an alternative therapy to treat pruritus.</p></sec></sec><sec id="Sec18"><title>Biliary diversion and nasogastric drainage</title><p id="Par81">Palliative treatment with biliary diversion surgery by the disruption of enterohepatic circulation may relieve pruritus and improve liver biochemical profiles. Several strategies have been used, including external biliary diversion or ileal exclusion [<xref ref-type="bibr" rid="CR108">108</xref>&#8211;<xref ref-type="bibr" rid="CR110">110</xref>].</p></sec><sec id="Sec19"><title>Liver transplantation</title><p id="Par82">Liver transplantation is considered a curative treatment for various liver diseases [<xref ref-type="bibr" rid="CR111">111</xref>]. However, for PFIC2 patients, the recurrence of the BSEP defect has been reported due to circulating BSEP antibodies [<xref ref-type="bibr" rid="CR112">112</xref>, <xref ref-type="bibr" rid="CR113">113</xref>]. Anti-CD20 antibody and plasmapheresis have been reported to treat recurrent BSEP deficiency [<xref ref-type="bibr" rid="CR114">114</xref>]. The outcomes in BSEP defects of common European mutations, such as D482G, are better than those of other mutation types [<xref ref-type="bibr" rid="CR85">85</xref>]. In addition, patients with multi-organ manifestations, such as diarrhea and pancreatic insufficiency in PFIC1, cannot be treated by liver transplantation.</p></sec><sec id="Sec20"><title>Liver tumor surveillance</title><p id="Par83">The disruption of bile acid transport not only causes PFIC but has also been associated with hepatocellular carcinoma and cholangiocarcinoma [<xref ref-type="bibr" rid="CR115">115</xref>, <xref ref-type="bibr" rid="CR116">116</xref>]. Patients with BSEP deficiency and tyrosinemia are of greater risk of developing hepatocellular carcinoma (HCC). It is mandatory that patients with PFIC be screened for liver tumors on a regular basis. Alpha-fetoprotein is not typically elevated. Some patients were found to have HCC in the explanted liver. Thirty-eight out of 175 pediatric HCC patients receiving liver transplantation were diagnosed with inherited liver diseases [<xref ref-type="bibr" rid="CR117">117</xref>].</p></sec><sec id="Sec21"><title>Hepatocyte transplantation and gene therapy</title><p id="Par84">Liver transplantation is often an ultimate option for patients with severe cholestasis, but the rarity of organ sources is an important issue. Hepatocyte transplantation might be an alternative therapy to use efficiently donor tissue in a less invasive manner. Cell therapy has been investigated in animal models with various extents of hepatocyte repopulation, including models of PFIC3 (<italic>Mdr2</italic> knockout mice), PFIC2 (<italic>Abcb11</italic> knockout mice) and hereditary tyrosinemia [<xref ref-type="bibr" rid="CR118">118</xref>&#8211;<xref ref-type="bibr" rid="CR120">120</xref>]. In previous studies, we found that UDCA can provide a selective growth advantage to donor hepatocytes in <italic>Abcb11</italic> knockout mice and enhance the repopulation of donor hepatocytes and partially correct the bile acid profile [<xref ref-type="bibr" rid="CR92">92</xref>]. However, insufficient long-term substitution ratio of donor hepatocyte in the livers of recipients, and the lack of donor cell sources limits the wide application of UDCA to treat clinical patients. For the past two decades, more than 20 patients with inherited liver-based metabolic disorders have received hepatocyte transplantation. Most of these patients showed only partial and transient improvements in metabolic function for several months and finally underwent liver transplantation [<xref ref-type="bibr" rid="CR121">121</xref>&#8211;<xref ref-type="bibr" rid="CR123">123</xref>]. Among these individuals, two patients with PFIC2 showed no obvious benefits after hepatocyte transplantation, as the existing fibrosis impaired the engraftment of the transplanted hepatocytes [<xref ref-type="bibr" rid="CR122">122</xref>]. Recently, glyceryl trinitrate have been shown to enhance the efficacy of the transplanted hepatocyte repopulation in <italic>Mdr2</italic> knockout mice [<xref ref-type="bibr" rid="CR124">124</xref>]. With additional treatment to boost donor cell repopulation, hepatocyte transplantation might be refined and benefit patients with cholestasis.</p><p id="Par85">Few studies on experimental gene therapy for cholestatic liver diseases have been reported. The adenoviral transfer of the aquaporin-1 gene has been shown to improve bile flow in rats with estrogen-induced cholestasis, but the effect in inherited cholestatic disease has not been validated [<xref ref-type="bibr" rid="CR125">125</xref>].</p></sec></sec><sec id="Sec22"><title>Conclusions</title><p id="Par86">With the revolutionary development of genetic analysis technologies, we have largely elucidated the molecular mechanisms of jaundice, bile flow and bile metabolism and identified new causes of genetic liver diseases that cause cholestasis. The understanding of &#8220;bile biology&#8221; not only provides insights into the mechanisms of liver pathophysiology but also facilitates the diagnosis of genetic liver diseases and the development of novel treatments.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>4-PB</term><def><p id="Par4">4-phenylbutyrate</p></def></def-item><def-item><term>A1AT</term><def><p id="Par5">Alpha 1-antitrypsin</p></def></def-item><def-item><term>ABC</term><def><p id="Par6">ATP-binding cassette</p></def></def-item><def-item><term>AFP</term><def><p id="Par7">Alpha-fetoprotein</p></def></def-item><def-item><term>ASBT</term><def><p id="Par8">Apical sodium dependent bile acid transporter</p></def></def-item><def-item><term>BAs</term><def><p id="Par9">Bile acids</p></def></def-item><def-item><term>BSEP</term><def><p id="Par10">Bile salt export pump</p></def></def-item><def-item><term>CA</term><def><p id="Par11">Cholic acid</p></def></def-item><def-item><term>CDCD</term><def><p id="Par12">Chenodeoxycholic acid</p></def></def-item><def-item><term>CYP</term><def><p id="Par13">Cytochrome P450</p></def></def-item><def-item><term>DCA</term><def><p id="Par14">Deoxycholic acid</p></def></def-item><def-item><term>DCDC2</term><def><p id="Par15">Doublecortin domain containing 2</p></def></def-item><def-item><term>FGFR4</term><def><p id="Par16">fibroblast growth factor receptor 4</p></def></def-item><def-item><term>FXR</term><def><p id="Par17">farnesoid X receptor</p></def></def-item><def-item><term>G(T)CA</term><def><p id="Par18">Glyco- or tauro-cholic acid</p></def></def-item><def-item><term>G(T)CDCA</term><def><p id="Par19">Glyco- or tauro-chenodeoxy cholic acid</p></def></def-item><def-item><term>GGT</term><def><p id="Par20">Gamma glutamyl transpeptidase</p></def></def-item><def-item><term>HCC</term><def><p id="Par21">Hepatocellular carcinoma</p></def></def-item><def-item><term>IEBAM</term><def><p id="Par22">Inborn error of bile acid metabolism</p></def></def-item><def-item><term>LCA</term><def><p id="Par23">Lithocholic acid</p></def></def-item><def-item><term>MDR2/3</term><def><p id="Par24">Multidrug resistance protein 2/3</p></def></def-item><def-item><term>MRP2/3/4</term><def><p id="Par25">Multidrug resistance-associated protein 2/3/4</p></def></def-item><def-item><term>MYO5B</term><def><p id="Par26">Myosin VB</p></def></def-item><def-item><term>NASH</term><def><p id="Par27">Nonalcoholic steatohepatitis</p></def></def-item><def-item><term>NH</term><def><p id="Par28">Neonatal hepatitis</p></def></def-item><def-item><term>NICCD</term><def><p id="Par29">Neonatal cholestasis caused by citrin deficiency</p></def></def-item><def-item><term>NTCP</term><def><p id="Par30">Sodium/taurocholate co-transporting polypeptide</p></def></def-item><def-item><term>OATP1B1/3</term><def><p id="Par31">Organic-anion-transporting polypeptide 1B1 and 1B3</p></def></def-item><def-item><term>OST&#945;/&#946;</term><def><p id="Par32">Organic solute transporter-&#945;/&#946;</p></def></def-item><def-item><term>PC</term><def><p id="Par33">Phosphatidylcholine</p></def></def-item><def-item><term>PFIC</term><def><p id="Par34">Progressive familial intrahepatic cholestasis</p></def></def-item><def-item><term>PS</term><def><p id="Par35">Phosphatidylserine</p></def></def-item><def-item><term>RXR&#945;</term><def><p id="Par36">Retinoid X receptor &#945;</p></def></def-item><def-item><term>SERPINA1</term><def><p id="Par37">Serpin family A member 1</p></def></def-item><def-item><term>SHP</term><def><p id="Par38">Small heterodimer partner</p></def></def-item><def-item><term>TFAM</term><def><p id="Par39">Mitochondrial transcription factor A</p></def></def-item><def-item><term>TGR5</term><def><p id="Par40">Takeda G protein-coupled receptor 5 (G protein-coupled bile acid receptor 1 , GPBAR1)</p></def></def-item><def-item><term>TJP2</term><def><p id="Par41">Tight junction protein 2</p></def></def-item><def-item><term>UDCA</term><def><p id="Par42">Ursodeoxycholic acid</p></def></def-item><def-item><term>UGT1A1</term><def><p id="Par43">UDP-glucuronosyltransferase 1A1</p></def></def-item></def-list></glossary><ack><sec id="FPar1"><title>Funding</title><p id="Par87">The authors&#8217; work is supported by grants from Ministry of Science and Technology, Taiwan (MOST105&#8211;2314-B-002-132-MY3).</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#8217; contributions</title><p>H-LC conceived the study and drafted the manuscript. S-HW drafted the manuscript. S-HH drafted the manuscript. B-YL drafted the manuscript. H-LC critically revised the manuscript. M-HC critically revised the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p>Not applicable</p></sec><sec id="FPar4"><title>Consent for publication</title><p>Not applicable (the manuscript does not content patient information).</p></sec><sec id="FPar5"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar6"><title>Publisher&#8217;s Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esteller</surname><given-names>A</given-names></name></person-group><article-title>Physiology of bile secretion</article-title><source>World J Gastroenterol</source><year>2008</year><volume>14</volume><fpage>5641</fpage><lpage>5649</lpage><pub-id pub-id-type="doi">10.3748/wjg.14.5641</pub-id><?supplied-pmid 18837079?><pub-id pub-id-type="pmid">18837079</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujiwara</surname><given-names>R</given-names></name><name><surname>Haag</surname><given-names>M</given-names></name><name><surname>Schaeffeler</surname><given-names>E</given-names></name><name><surname>Nies</surname><given-names>AT</given-names></name><name><surname>Zanger</surname><given-names>UM</given-names></name><name><surname>Schwab</surname><given-names>M</given-names></name></person-group><article-title>Systemic regulation of bilirubin homeostasis: potential benefits of hyperbilirubinemia</article-title><source>Hepatology</source><year>2018</year><volume>67</volume><fpage>1609</fpage><lpage>1619</lpage><pub-id pub-id-type="doi">10.1002/hep.29599</pub-id><?supplied-pmid 29059457?><pub-id pub-id-type="pmid">29059457</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sticova</surname><given-names>E</given-names></name><name><surname>Jirsa</surname><given-names>M</given-names></name></person-group><article-title>New insights in bilirubin metabolism and their clinical implications</article-title><source>World J Gastroenterol</source><year>2013</year><volume>19</volume><fpage>6398</fpage><lpage>6407</lpage><pub-id pub-id-type="doi">10.3748/wjg.v19.i38.6398</pub-id><?supplied-pmid 24151358?><pub-id pub-id-type="pmid">24151358</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sedlak</surname><given-names>TW</given-names></name><name><surname>Saleh</surname><given-names>M</given-names></name><name><surname>Higginson</surname><given-names>DS</given-names></name><name><surname>Paul</surname><given-names>BD</given-names></name><name><surname>Juluri</surname><given-names>KR</given-names></name><name><surname>Snyder</surname><given-names>SH</given-names></name></person-group><article-title>Bilirubin and glutathione have complementary antioxidant and cytoprotective roles</article-title><source>Proc Natl Acad Sci U S A</source><year>2009</year><volume>106</volume><fpage>5171</fpage><lpage>5176</lpage><pub-id pub-id-type="doi">10.1073/pnas.0813132106</pub-id><?supplied-pmid 19286972?><pub-id pub-id-type="pmid">19286972</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>JY</given-names></name></person-group><article-title>Bile acid regulation of gene expression: roles of nuclear hormone receptors</article-title><source>Endocr Rev</source><year>2002</year><volume>23</volume><fpage>443</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1210/er.2000-0035</pub-id><?supplied-pmid 12202460?><pub-id pub-id-type="pmid">12202460</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molinaro</surname><given-names>A</given-names></name><name><surname>Wahlstrom</surname><given-names>A</given-names></name><name><surname>Marschall</surname><given-names>HU</given-names></name></person-group><article-title>Role of bile acids in metabolic control</article-title><source>Trends Endocrinol Metab</source><year>2018</year><volume>29</volume><fpage>31</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2017.11.002</pub-id><?supplied-pmid 29195686?><pub-id pub-id-type="pmid">29195686</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinot</surname><given-names>E</given-names></name><name><surname>Sedes</surname><given-names>L</given-names></name><name><surname>Baptissart</surname><given-names>M</given-names></name><name><surname>Lobaccaro</surname><given-names>JM</given-names></name><name><surname>Caira</surname><given-names>F</given-names></name><name><surname>Beaudoin</surname><given-names>C</given-names></name><name><surname>Volle</surname><given-names>DH</given-names></name></person-group><article-title>Bile acids and their receptors</article-title><source>Mol Asp Med</source><year>2017</year><volume>56</volume><fpage>2</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.mam.2017.01.006</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reshetnyak</surname><given-names>VI</given-names></name></person-group><article-title>Physiological and molecular biochemical mechanisms of bile formation</article-title><source>World J Gastroenterol</source><year>2013</year><volume>19</volume><fpage>7341</fpage><lpage>7360</lpage><pub-id pub-id-type="doi">10.3748/wjg.v19.i42.7341</pub-id><?supplied-pmid 24259965?><pub-id pub-id-type="pmid">24259965</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>DW</given-names></name></person-group><article-title>The enzymes, regulation, and genetics of bile acid synthesis</article-title><source>Annu Rev Biochem</source><year>2003</year><volume>72</volume><fpage>137</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1146/annurev.biochem.72.121801.161712</pub-id><pub-id pub-id-type="pmid">12543708</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J</given-names></name><name><surname>Vandeberg</surname><given-names>JL</given-names></name></person-group><article-title>Hepatobiliary transport in health and disease</article-title><source>Clin Lipidol</source><year>2012</year><volume>7</volume><fpage>189</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.2217/clp.12.12</pub-id><?supplied-pmid 22859919?><pub-id pub-id-type="pmid">22859919</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>GM</given-names></name><name><surname>Signer</surname><given-names>E</given-names></name></person-group><article-title>Bile acid metabolism in infants and children</article-title><source>Gut</source><year>1974</year><volume>15</volume><fpage>151</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1136/gut.15.2.151</pub-id><?supplied-pmid 4595082?><pub-id pub-id-type="pmid">4595082</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Claro da Silva</surname><given-names>T</given-names></name><name><surname>Polli</surname><given-names>JE</given-names></name><name><surname>Swaan</surname><given-names>PW</given-names></name></person-group><article-title>The solute carrier family 10 (SLC10): beyond bile acid transport</article-title><source>Mol Asp Med</source><year>2013</year><volume>34</volume><fpage>252</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1016/j.mam.2012.07.004</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballatori</surname><given-names>N</given-names></name><name><surname>Christian</surname><given-names>WV</given-names></name><name><surname>Wheeler</surname><given-names>SG</given-names></name><name><surname>Hammond</surname><given-names>CL</given-names></name></person-group><article-title>The heteromeric organic solute transporter, OSTalpha-OSTbeta/SLC51: a transporter for steroid-derived molecules</article-title><source>Mol Asp Med</source><year>2013</year><volume>34</volume><fpage>683</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1016/j.mam.2012.11.005</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawson</surname><given-names>PA</given-names></name><name><surname>Hubbert</surname><given-names>ML</given-names></name><name><surname>Rao</surname><given-names>A</given-names></name></person-group><article-title>Getting the mOST from OST: role of organic solute transporter, OSTalpha-OSTbeta, in bile acid and steroid metabolism</article-title><source>Biochim Biophys Acta</source><year>2010</year><volume>1801</volume><fpage>994</fpage><lpage>1004</lpage><pub-id pub-id-type="doi">10.1016/j.bbalip.2010.06.002</pub-id><?supplied-pmid 20538072?><pub-id pub-id-type="pmid">20538072</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suga</surname><given-names>T</given-names></name><name><surname>Yamaguchi</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Maekawa</surname><given-names>M</given-names></name><name><surname>Goto</surname><given-names>J</given-names></name><name><surname>Mano</surname><given-names>N</given-names></name></person-group><article-title>Preference of conjugated bile acids over unconjugated bile acids as substrates for OATP1B1 and OATP1B3</article-title><source>PLoS One</source><year>2017</year><volume>12</volume><fpage>e0169719</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0169719</pub-id><?supplied-pmid 28060902?><pub-id pub-id-type="pmid">28060902</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keppler</surname><given-names>D</given-names></name></person-group><article-title>The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia</article-title><source>Drug Metab Dispos</source><year>2014</year><volume>42</volume><fpage>561</fpage><lpage>565</lpage><pub-id pub-id-type="doi">10.1124/dmd.113.055772</pub-id><?supplied-pmid 24459177?><pub-id pub-id-type="pmid">24459177</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schroeder</surname><given-names>RJ</given-names></name><name><surname>Ahmed</surname><given-names>SN</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>London</surname><given-names>E</given-names></name><name><surname>Brown</surname><given-names>DA</given-names></name></person-group><article-title>Cholesterol and sphingolipid enhance the triton X-100 insolubility of glycosylphosphatidylinositol-anchored proteins by promoting the formation of detergent-insoluble ordered membrane domains</article-title><source>J Biol Chem</source><year>1998</year><volume>273</volume><fpage>1150</fpage><lpage>1157</lpage><pub-id pub-id-type="doi">10.1074/jbc.273.2.1150</pub-id><?supplied-pmid 9422781?><pub-id pub-id-type="pmid">9422781</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guyot</surname><given-names>C</given-names></name><name><surname>Stieger</surname><given-names>B</given-names></name></person-group><article-title>Interaction of bile salts with rat canalicular membrane vesicles: evidence for bile salt resistant microdomains</article-title><source>J Hepatol</source><year>2011</year><volume>55</volume><fpage>1368</fpage><lpage>1376</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2011.04.014</pub-id><?supplied-pmid 21703191?><pub-id pub-id-type="pmid">21703191</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linton</surname><given-names>KJ</given-names></name></person-group><article-title>Lipid flopping in the liver</article-title><source>Biochem Soc Trans</source><year>2015</year><volume>43</volume><fpage>1003</fpage><lpage>1010</lpage><pub-id pub-id-type="doi">10.1042/BST20150132</pub-id><?supplied-pmid 26517915?><pub-id pub-id-type="pmid">26517915</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groen</surname><given-names>Annemiek</given-names></name><name><surname>Romero</surname><given-names>Marta Rodriguez</given-names></name><name><surname>Kunne</surname><given-names>Cindy</given-names></name><name><surname>Hoosdally</surname><given-names>Sarah J.</given-names></name><name><surname>Dixon</surname><given-names>Peter H.</given-names></name><name><surname>Wooding</surname><given-names>Carol</given-names></name><name><surname>Williamson</surname><given-names>Catherine</given-names></name><name><surname>Seppen</surname><given-names>Jurgen</given-names></name><name><surname>van den Oever</surname><given-names>Karin</given-names></name><name><surname>Mok</surname><given-names>Kam S.</given-names></name><name><surname>Paulusma</surname><given-names>Coen C.</given-names></name><name><surname>Linton</surname><given-names>Kenneth J.</given-names></name><name><surname>Oude Elferink</surname><given-names>Ronald P.J.</given-names></name></person-group><article-title>Complementary Functions of the Flippase ATP8B1 and the Floppase ABCB4 in Maintaining Canalicular Membrane Integrity</article-title><source>Gastroenterology</source><year>2011</year><volume>141</volume><issue>5</issue><fpage>1927-1937.e4</fpage><pub-id pub-id-type="doi">10.1053/j.gastro.2011.07.042</pub-id><pub-id pub-id-type="pmid">21820390</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Hollister</surname><given-names>K</given-names></name><name><surname>Sowers</surname><given-names>LC</given-names></name><name><surname>Forman</surname><given-names>BM</given-names></name></person-group><article-title>Endogenous bile acids are ligands for the nuclear receptor FXR/BAR</article-title><source>Mol Cell</source><year>1999</year><volume>3</volume><fpage>543</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(00)80348-2</pub-id><?supplied-pmid 10360171?><pub-id pub-id-type="pmid">10360171</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parks</surname><given-names>DJ</given-names></name><name><surname>Blanchard</surname><given-names>SG</given-names></name><name><surname>Bledsoe</surname><given-names>RK</given-names></name><name><surname>Chandra</surname><given-names>G</given-names></name><name><surname>Consler</surname><given-names>TG</given-names></name><name><surname>Kliewer</surname><given-names>SA</given-names></name><name><surname>Stimmel</surname><given-names>JB</given-names></name><etal/></person-group><article-title>Bile acids: natural ligands for an orphan nuclear receptor</article-title><source>Science</source><year>1999</year><volume>284</volume><fpage>1365</fpage><lpage>1368</lpage><pub-id pub-id-type="doi">10.1126/science.284.5418.1365</pub-id><pub-id pub-id-type="pmid">10334993</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makishima</surname><given-names>M</given-names></name><name><surname>Okamoto</surname><given-names>AY</given-names></name><name><surname>Repa</surname><given-names>JJ</given-names></name><name><surname>Tu</surname><given-names>H</given-names></name><name><surname>Learned</surname><given-names>RM</given-names></name><name><surname>Luk</surname><given-names>A</given-names></name><name><surname>Hull</surname><given-names>MV</given-names></name><etal/></person-group><article-title>Identification of a nuclear receptor for bile acids</article-title><source>Science</source><year>1999</year><volume>284</volume><fpage>1362</fpage><lpage>1365</lpage><pub-id pub-id-type="doi">10.1126/science.284.5418.1362</pub-id><?supplied-pmid 10334992?><pub-id pub-id-type="pmid">10334992</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Modica</surname><given-names>S</given-names></name><name><surname>Gadaleta</surname><given-names>RM</given-names></name><name><surname>Moschetta</surname><given-names>A</given-names></name></person-group><article-title>Deciphering the nuclear bile acid receptor FXR paradigm</article-title><source>Nucl Recept Signal</source><year>2010</year><volume>8</volume><fpage>e005</fpage><pub-id pub-id-type="doi">10.1621/nrs.08005</pub-id><?supplied-pmid 21383957?><pub-id pub-id-type="pmid">21383957</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodwin</surname><given-names>B</given-names></name><name><surname>Jones</surname><given-names>SA</given-names></name><name><surname>Price</surname><given-names>RR</given-names></name><name><surname>Watson</surname><given-names>MA</given-names></name><name><surname>McKee</surname><given-names>DD</given-names></name><name><surname>Moore</surname><given-names>LB</given-names></name><name><surname>Galardi</surname><given-names>C</given-names></name><etal/></person-group><article-title>A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis</article-title><source>Mol Cell</source><year>2000</year><volume>6</volume><fpage>517</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(00)00051-4</pub-id><?supplied-pmid 11030332?><pub-id pub-id-type="pmid">11030332</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Pan</surname><given-names>LX</given-names></name><name><surname>Shang</surname><given-names>Q</given-names></name><name><surname>Honda</surname><given-names>A</given-names></name><name><surname>Ananthanarayanan</surname><given-names>M</given-names></name><name><surname>Erickson</surname><given-names>SK</given-names></name><etal/></person-group><article-title>FXR-mediated down-regulation of CYP7A1 dominates LXRalpha in long-term cholesterol-fed NZW rabbits</article-title><source>J Lipid Res</source><year>2003</year><volume>44</volume><fpage>1956</fpage><lpage>1962</lpage><pub-id pub-id-type="doi">10.1194/jlr.M300182-JLR200</pub-id><?supplied-pmid 12897188?><pub-id pub-id-type="pmid">12897188</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balasubramaniyan</surname><given-names>N</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>AQ</given-names></name><name><surname>Suchy</surname><given-names>FJ</given-names></name></person-group><article-title>SUMOylation of the farnesoid X receptor (FXR) regulates the expression of FXR target genes</article-title><source>J Biol Chem</source><year>2013</year><volume>288</volume><fpage>13850</fpage><lpage>13862</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.443937</pub-id><?supplied-pmid 23546875?><pub-id pub-id-type="pmid">23546875</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>M</given-names></name><name><surname>Fickert</surname><given-names>P</given-names></name><name><surname>Zollner</surname><given-names>G</given-names></name><name><surname>Fuchsbichler</surname><given-names>A</given-names></name><name><surname>Silbert</surname><given-names>D</given-names></name><name><surname>Tsybrovskyy</surname><given-names>O</given-names></name><name><surname>Zatloukal</surname><given-names>K</given-names></name><etal/></person-group><article-title>Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice</article-title><source>Gastroenterology</source><year>2003</year><volume>125</volume><fpage>825</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1016/S0016-5085(03)01068-0</pub-id><?supplied-pmid 12949728?><pub-id pub-id-type="pmid">12949728</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyer</surname><given-names>JL</given-names></name><name><surname>Trauner</surname><given-names>M</given-names></name><name><surname>Mennone</surname><given-names>A</given-names></name><name><surname>Soroka</surname><given-names>CJ</given-names></name><name><surname>Cai</surname><given-names>SY</given-names></name><name><surname>Moustafa</surname><given-names>T</given-names></name><name><surname>Zollner</surname><given-names>G</given-names></name><etal/></person-group><article-title>Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents</article-title><source>Am J Physiol Gastrointest Liver Physiol</source><year>2006</year><volume>290</volume><fpage>G1124</fpage><lpage>G1130</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00539.2005</pub-id><?supplied-pmid 16423920?><pub-id pub-id-type="pmid">16423920</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kullak-Ublick</surname><given-names>GA</given-names></name><name><surname>Stieger</surname><given-names>B</given-names></name><name><surname>Meier</surname><given-names>PJ</given-names></name></person-group><article-title>Enterohepatic bile salt transporters in normal physiology and liver disease</article-title><source>Gastroenterology</source><year>2004</year><volume>126</volume><fpage>322</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2003.06.005</pub-id><?supplied-pmid 14699511?><pub-id pub-id-type="pmid">14699511</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geier</surname><given-names>A</given-names></name><name><surname>Wagner</surname><given-names>M</given-names></name><name><surname>Dietrich</surname><given-names>CG</given-names></name><name><surname>Trauner</surname><given-names>M</given-names></name></person-group><article-title>Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration</article-title><source>Biochim Biophys Acta</source><year>2007</year><volume>1773</volume><fpage>283</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2006.04.014</pub-id><?supplied-pmid 17291602?><pub-id pub-id-type="pmid">17291602</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Shang</surname><given-names>Q</given-names></name><name><surname>Pan</surname><given-names>L</given-names></name><name><surname>Shneider</surname><given-names>BL</given-names></name><name><surname>Chiang</surname><given-names>JY</given-names></name><name><surname>Forman</surname><given-names>BM</given-names></name><etal/></person-group><article-title>FXR-activating ligands inhibit rabbit ASBT expression via FXR-SHP-FTF cascade</article-title><source>Am J Physiol Gastrointest Liver Physiol</source><year>2005</year><volume>288</volume><fpage>G60</fpage><lpage>G66</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00170.2004</pub-id><?supplied-pmid 15591588?><pub-id pub-id-type="pmid">15591588</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neimark</surname><given-names>E</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Shneider</surname><given-names>BL</given-names></name></person-group><article-title>Bile acid-induced negative feedback regulation of the human ileal bile acid transporter</article-title><source>Hepatology</source><year>2004</year><volume>40</volume><fpage>149</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1002/hep.20295</pub-id><?supplied-pmid 15239098?><pub-id pub-id-type="pmid">15239098</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inagaki</surname><given-names>T</given-names></name><name><surname>Moschetta</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>YK</given-names></name><name><surname>Peng</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>Downes</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>RT</given-names></name><etal/></person-group><article-title>Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor</article-title><source>Proc Natl Acad Sci U S A</source><year>2006</year><volume>103</volume><fpage>3920</fpage><lpage>3925</lpage><pub-id pub-id-type="doi">10.1073/pnas.0509592103</pub-id><?supplied-pmid 16473946?><pub-id pub-id-type="pmid">16473946</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>CS</given-names></name></person-group><article-title>Molecular genetics of unconjugated hyperbilirubinemia in Taiwanese</article-title><source>J Biomed Sci</source><year>2005</year><volume>12</volume><fpage>445</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1007/s11373-005-3863-5</pub-id><?supplied-pmid 15965581?><pub-id pub-id-type="pmid">15965581</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Memon</surname><given-names>N</given-names></name><name><surname>Weinberger</surname><given-names>BI</given-names></name><name><surname>Hegyi</surname><given-names>T</given-names></name><name><surname>Aleksunes</surname><given-names>LM</given-names></name></person-group><article-title>Inherited disorders of bilirubin clearance</article-title><source>Pediatr Res</source><year>2016</year><volume>79</volume><fpage>378</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1038/pr.2015.247</pub-id><?supplied-pmid 26595536?><pub-id pub-id-type="pmid">26595536</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>HC</given-names></name><name><surname>Chen</surname><given-names>MH</given-names></name><name><surname>Yang</surname><given-names>HI</given-names></name><name><surname>Su</surname><given-names>YN</given-names></name><name><surname>Hsieh</surname><given-names>WS</given-names></name><name><surname>Chen</surname><given-names>CY</given-names></name><name><surname>Chen</surname><given-names>HL</given-names></name><etal/></person-group><article-title>211 G to a variation of UDP-glucuronosyl transferase 1A1 gene and neonatal breastfeeding jaundice</article-title><source>Pediatr Res</source><year>2011</year><volume>69</volume><fpage>170</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1203/PDR.0b013e31820263d2</pub-id><?supplied-pmid 20975617?><pub-id pub-id-type="pmid">20975617</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>PF</given-names></name><name><surname>Lin</surname><given-names>YC</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Yeh</surname><given-names>SJ</given-names></name><name><surname>Ni</surname><given-names>YH</given-names></name></person-group><article-title>Risk of hyperbilirubinemia in breast-fed infants</article-title><source>J Pediatr</source><year>2011</year><volume>159</volume><fpage>561</fpage><lpage>565</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2011.03.042</pub-id><?supplied-pmid 21592495?><pub-id pub-id-type="pmid">21592495</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jansen</surname><given-names>PL</given-names></name><name><surname>Sturm</surname><given-names>E</given-names></name></person-group><article-title>Genetic cholestasis, causes and consequences for hepatobiliary transport</article-title><source>Liver Int</source><year>2003</year><volume>23</volume><fpage>315</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1034/j.1478-3231.2003.00856.x</pub-id><?supplied-pmid 14708891?><pub-id pub-id-type="pmid">14708891</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>JL</given-names></name><name><surname>Choquette</surname><given-names>M</given-names></name><name><surname>Bezerra</surname><given-names>JA</given-names></name></person-group><article-title>Cholestatic liver disease in children</article-title><source>Curr Gastroenterol Rep</source><year>2010</year><volume>12</volume><fpage>30</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1007/s11894-009-0081-8</pub-id><?supplied-pmid 20425482?><pub-id pub-id-type="pmid">20425482</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="other">A W. Medical management of chronic cholestasis. In: Walker&#8217;s Pediatric Gastrointestinal Diseases. BC Decker Inc: Hamilton. 2008:797&#8211;799.</mixed-citation></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="other">Loomes KM, Emerick KM. Pediatric cholestatic liver disease. In: Wyllie R, Hyams JS, Kay M ed. Pediatric gastrointestinal and liver disease. 5th edition. Elsevier (Philadelphia, PA) 2016:851&#8211;869.</mixed-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Kelly</surname><given-names>Deirdre A.</given-names></name></person-group><source>Diseases of the Liver and Biliary System in Children</source><year>2017</year><publisher-loc>Chichester, UK</publisher-loc><publisher-name>John Wiley &amp; Sons, Ltd</publisher-name></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>HL</given-names></name><name><surname>Chang</surname><given-names>PS</given-names></name><name><surname>Hsu</surname><given-names>HC</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Ni</surname><given-names>YH</given-names></name><name><surname>Hsu</surname><given-names>HY</given-names></name><name><surname>Jeng</surname><given-names>YM</given-names></name><etal/></person-group><article-title>Progressive familial intrahepatic cholestasis with high gamma-glutamyltranspeptidase levels in Taiwanese infants: role of MDR3 gene defect?</article-title><source>Pediatr Res</source><year>2001</year><volume>50</volume><fpage>50</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1203/00006450-200107000-00011</pub-id><?supplied-pmid 11420418?><pub-id pub-id-type="pmid">11420418</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>HL</given-names></name><name><surname>Chang</surname><given-names>PS</given-names></name><name><surname>Hsu</surname><given-names>HC</given-names></name><name><surname>Ni</surname><given-names>YH</given-names></name><name><surname>Hsu</surname><given-names>HY</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Jeng</surname><given-names>YM</given-names></name><etal/></person-group><article-title>FIC1 and BSEP defects in Taiwanese patients with chronic intrahepatic cholestasis with low gamma-glutamyltranspeptidase levels</article-title><source>J Pediatr</source><year>2002</year><volume>140</volume><fpage>119</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1067/mpd.2002.119993</pub-id><?supplied-pmid 11815775?><pub-id pub-id-type="pmid">11815775</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>HL</given-names></name><name><surname>Liu</surname><given-names>YJ</given-names></name><name><surname>Su</surname><given-names>YN</given-names></name><name><surname>Wang</surname><given-names>NY</given-names></name><name><surname>Wu</surname><given-names>SH</given-names></name><name><surname>Ni</surname><given-names>YH</given-names></name><name><surname>Hsu</surname><given-names>HY</given-names></name><etal/></person-group><article-title>Diagnosis of BSEP/ABCB11 mutations in Asian patients with cholestasis using denaturing high performance liquid chromatography</article-title><source>J Pediatr</source><year>2008</year><volume>153</volume><fpage>825</fpage><lpage>832</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2008.06.034</pub-id><?supplied-pmid 18692205?><pub-id pub-id-type="pmid">18692205</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>YC</given-names></name><name><surname>Chen</surname><given-names>HL</given-names></name><name><surname>Wu</surname><given-names>MZ</given-names></name><name><surname>Liu</surname><given-names>YJ</given-names></name><name><surname>Lee</surname><given-names>PH</given-names></name><name><surname>Sheu</surname><given-names>JC</given-names></name><name><surname>Chen</surname><given-names>CH</given-names></name></person-group><article-title>Adult progressive intrahepatic cholestasis associated with genetic variations in ATP8B1 and ABCB11</article-title><source>Hepatol Res</source><year>2009</year><volume>39</volume><fpage>625</fpage><lpage>631</lpage><pub-id pub-id-type="doi">10.1111/j.1872-034X.2009.00499.x</pub-id><?supplied-pmid 19260995?><pub-id pub-id-type="pmid">19260995</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lien</surname><given-names>TH</given-names></name><name><surname>Chang</surname><given-names>MH</given-names></name><name><surname>Wu</surname><given-names>JF</given-names></name><name><surname>Chen</surname><given-names>HL</given-names></name><name><surname>Lee</surname><given-names>HC</given-names></name><name><surname>Chen</surname><given-names>AC</given-names></name><name><surname>Tiao</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Effects of the infant stool color card screening program on 5-year outcome of biliary atresia in Taiwan</article-title><source>Hepatology</source><year>2011</year><volume>53</volume><fpage>202</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1002/hep.24023</pub-id><?supplied-pmid 21140377?><pub-id pub-id-type="pmid">21140377</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>HL</given-names></name><name><surname>Liu</surname><given-names>YJ</given-names></name><name><surname>Chen</surname><given-names>HL</given-names></name><name><surname>Wu</surname><given-names>SH</given-names></name><name><surname>Ni</surname><given-names>YH</given-names></name><name><surname>Ho</surname><given-names>MC</given-names></name><name><surname>Lai</surname><given-names>HS</given-names></name><etal/></person-group><article-title>Expression of hepatocyte transporters and nuclear receptors in children with early and late-stage biliary atresia</article-title><source>Pediatr Res</source><year>2008</year><volume>63</volume><fpage>667</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1203/PDR.0b013e318170a6b5</pub-id><?supplied-pmid 18327154?><pub-id pub-id-type="pmid">18327154</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strautnieks</surname><given-names>SS</given-names></name><name><surname>Bull</surname><given-names>LN</given-names></name><name><surname>Knisely</surname><given-names>AS</given-names></name><name><surname>Kocoshis</surname><given-names>SA</given-names></name><name><surname>Dahl</surname><given-names>N</given-names></name><name><surname>Arnell</surname><given-names>H</given-names></name><name><surname>Sokal</surname><given-names>E</given-names></name><etal/></person-group><article-title>A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis</article-title><source>Nat Genet</source><year>1998</year><volume>20</volume><fpage>233</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1038/3034</pub-id><?supplied-pmid 9806540?><pub-id pub-id-type="pmid">9806540</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bull</surname><given-names>LN</given-names></name><name><surname>van Eijk</surname><given-names>MJ</given-names></name><name><surname>Pawlikowska</surname><given-names>L</given-names></name><name><surname>DeYoung</surname><given-names>JA</given-names></name><name><surname>Juijn</surname><given-names>JA</given-names></name><name><surname>Liao</surname><given-names>M</given-names></name><name><surname>Klomp</surname><given-names>LW</given-names></name><etal/></person-group><article-title>A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis</article-title><source>Nat Genet</source><year>1998</year><volume>18</volume><fpage>219</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1038/ng0398-219</pub-id><?supplied-pmid 9500542?><pub-id pub-id-type="pmid">9500542</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Vree</surname><given-names>JM</given-names></name><name><surname>Jacquemin</surname><given-names>E</given-names></name><name><surname>Sturm</surname><given-names>E</given-names></name><name><surname>Cresteil</surname><given-names>D</given-names></name><name><surname>Bosma</surname><given-names>PJ</given-names></name><name><surname>Aten</surname><given-names>J</given-names></name><name><surname>Deleuze</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis</article-title><source>Proc Natl Acad Sci U S A</source><year>1998</year><volume>95</volume><fpage>282</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.1.282</pub-id><?supplied-pmid 9419367?><pub-id pub-id-type="pmid">9419367</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>R</given-names></name><name><surname>Strautnieks</surname><given-names>S</given-names></name></person-group><article-title>BSEP: function and role in progressive familial intrahepatic cholestasis</article-title><source>Semin Liver Dis</source><year>2001</year><volume>21</volume><fpage>545</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1055/s-2001-19038</pub-id><?supplied-pmid 11745042?><pub-id pub-id-type="pmid">11745042</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Ospina</surname><given-names>N</given-names></name><name><surname>Potter</surname><given-names>CJ</given-names></name><name><surname>Xiao</surname><given-names>R</given-names></name><name><surname>Manickam</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>MS</given-names></name><name><surname>Kim</surname><given-names>KH</given-names></name><name><surname>Shneider</surname><given-names>BL</given-names></name><etal/></person-group><article-title>Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis</article-title><source>Nat Commun</source><year>2016</year><volume>7</volume><fpage>10713</fpage><pub-id pub-id-type="doi">10.1038/ncomms10713</pub-id><?supplied-pmid 26888176?><pub-id pub-id-type="pmid">26888176</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><mixed-citation publication-type="other">Chen HL LH, Wu JF, Wu SH, Chen HL, Yang YH, Hsu YH, Liou BY, Chang MH, Ni YH. Panel-based Next-Generation Sequencing for the Diagnosis of Cholestatic Genetic Liver Diseases: Clinical Utility and Challenges. J Pediatr. 2018;(in press).</mixed-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sambrotta</surname><given-names>M</given-names></name><name><surname>Strautnieks</surname><given-names>S</given-names></name><name><surname>Papouli</surname><given-names>E</given-names></name><name><surname>Rushton</surname><given-names>P</given-names></name><name><surname>Clark</surname><given-names>BE</given-names></name><name><surname>Parry</surname><given-names>DA</given-names></name><name><surname>Logan</surname><given-names>CV</given-names></name><etal/></person-group><article-title>Mutations in TJP2 cause progressive cholestatic liver disease</article-title><source>Nat Genet</source><year>2014</year><volume>46</volume><fpage>326</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1038/ng.2918</pub-id><?supplied-pmid 24614073?><pub-id pub-id-type="pmid">24614073</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>YL</given-names></name><name><surname>Gong</surname><given-names>JY</given-names></name><name><surname>Feng</surname><given-names>JY</given-names></name><name><surname>Wang</surname><given-names>RX</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Defects in myosin VB are associated with a spectrum of previously undiagnosed low gamma-glutamyltransferase cholestasis</article-title><source>Hepatology</source><year>2017</year><volume>65</volume><fpage>1655</fpage><lpage>1669</lpage><pub-id pub-id-type="doi">10.1002/hep.29020</pub-id><?supplied-pmid 28027573?><pub-id pub-id-type="pmid">28027573</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzales</surname><given-names>E</given-names></name><name><surname>Taylor</surname><given-names>SA</given-names></name><name><surname>Davit-Spraul</surname><given-names>A</given-names></name><name><surname>Thebaut</surname><given-names>A</given-names></name><name><surname>Thomassin</surname><given-names>N</given-names></name><name><surname>Guettier</surname><given-names>C</given-names></name><name><surname>Whitington</surname><given-names>PF</given-names></name><etal/></person-group><article-title>MYO5B mutations cause cholestasis with normal serum gamma-glutamyl transferase activity in children without microvillous inclusion disease</article-title><source>Hepatology</source><year>2017</year><volume>65</volume><fpage>164</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1002/hep.28779</pub-id><?supplied-pmid 27532546?><pub-id pub-id-type="pmid">27532546</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schueler</surname><given-names>M</given-names></name><name><surname>Braun</surname><given-names>DA</given-names></name><name><surname>Chandrasekar</surname><given-names>G</given-names></name><name><surname>Gee</surname><given-names>HY</given-names></name><name><surname>Klasson</surname><given-names>TD</given-names></name><name><surname>Halbritter</surname><given-names>J</given-names></name><name><surname>Bieder</surname><given-names>A</given-names></name><etal/></person-group><article-title>DCDC2 mutations cause a renal-hepatic ciliopathy by disrupting Wnt signaling</article-title><source>Am J Hum Genet</source><year>2015</year><volume>96</volume><fpage>81</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2014.12.002</pub-id><?supplied-pmid 25557784?><pub-id pub-id-type="pmid">25557784</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grammatikopoulos</surname><given-names>T</given-names></name><name><surname>Sambrotta</surname><given-names>M</given-names></name><name><surname>Strautnieks</surname><given-names>S</given-names></name><name><surname>Foskett</surname><given-names>P</given-names></name><name><surname>Knisely</surname><given-names>AS</given-names></name><name><surname>Wagner</surname><given-names>B</given-names></name><name><surname>Deheragoda</surname><given-names>M</given-names></name><etal/></person-group><article-title>Mutations in DCDC2 (doublecortin domain containing protein 2) in neonatal sclerosing cholangitis</article-title><source>J Hepatol</source><year>2016</year><volume>65</volume><fpage>1179</fpage><lpage>1187</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2016.07.017</pub-id><?supplied-pmid 27469900?><pub-id pub-id-type="pmid">27469900</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girard</surname><given-names>M</given-names></name><name><surname>Bizet</surname><given-names>AA</given-names></name><name><surname>Lachaux</surname><given-names>A</given-names></name><name><surname>Gonzales</surname><given-names>E</given-names></name><name><surname>Filhol</surname><given-names>E</given-names></name><name><surname>Collardeau-Frachon</surname><given-names>S</given-names></name><name><surname>Jeanpierre</surname><given-names>C</given-names></name><etal/></person-group><article-title>DCDC2 mutations cause neonatal Sclerosing cholangitis</article-title><source>Hum Mutat</source><year>2016</year><volume>37</volume><fpage>1025</fpage><lpage>1029</lpage><pub-id pub-id-type="doi">10.1002/humu.23031</pub-id><?supplied-pmid 27319779?><pub-id pub-id-type="pmid">27319779</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stiles</surname><given-names>AR</given-names></name><name><surname>Simon</surname><given-names>MT</given-names></name><name><surname>Stover</surname><given-names>A</given-names></name><name><surname>Eftekharian</surname><given-names>S</given-names></name><name><surname>Khanlou</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>HL</given-names></name><name><surname>Magaki</surname><given-names>S</given-names></name><etal/></person-group><article-title>Mutations in TFAM, encoding mitochondrial transcription factor a, cause neonatal liver failure associated with mtDNA depletion</article-title><source>Mol Genet Metab</source><year>2016</year><volume>119</volume><fpage>91</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/j.ymgme.2016.07.001</pub-id><?supplied-pmid 27448789?><pub-id pub-id-type="pmid">27448789</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sultan</surname><given-names>Mutaz</given-names></name><name><surname>Rao</surname><given-names>Anuradha</given-names></name><name><surname>Elpeleg</surname><given-names>Orly</given-names></name><name><surname>Vaz</surname><given-names>Fr&#233;d&#233;ric M.</given-names></name><name><surname>Abu-Libdeh</surname><given-names>Bassam</given-names></name><name><surname>Karpen</surname><given-names>Saul J.</given-names></name><name><surname>Dawson</surname><given-names>Paul A.</given-names></name></person-group><article-title>Organic solute transporter-&#946; (SLC51B ) deficiency in two brothers with congenital diarrhea and features of cholestasis</article-title><source>Hepatology</source><year>2018</year><volume>68</volume><issue>2</issue><fpage>590</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1002/hep.29516</pub-id><?supplied-pmid 28898457?><pub-id pub-id-type="pmid">28898457</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Chen</surname><given-names>HL</given-names></name><name><surname>Chen</surname><given-names>HL</given-names></name><name><surname>Ni</surname><given-names>YH</given-names></name><name><surname>Hsu</surname><given-names>HY</given-names></name><name><surname>Chang</surname><given-names>MH</given-names></name></person-group><article-title>Neonatal Dubin-Johnson syndrome: long-term follow-up and MRP2 mutations study</article-title><source>Pediatr Res</source><year>2006</year><volume>59</volume><fpage>584</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1203/01.pdr.0000203093.10908.bb</pub-id><?supplied-pmid 16549534?><pub-id pub-id-type="pmid">16549534</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Togawa</surname><given-names>Takao</given-names></name><name><surname>Sugiura</surname><given-names>Tokio</given-names></name><name><surname>Ito</surname><given-names>Koichi</given-names></name><name><surname>Endo</surname><given-names>Takeshi</given-names></name><name><surname>Aoyama</surname><given-names>Kohei</given-names></name><name><surname>Ohashi</surname><given-names>Kei</given-names></name><name><surname>Negishi</surname><given-names>Yutaka</given-names></name><name><surname>Kudo</surname><given-names>Toyoichiro</given-names></name><name><surname>Ito</surname><given-names>Reiko</given-names></name><name><surname>Kikuchi</surname><given-names>Atsuo</given-names></name><name><surname>Arai-Ichinoi</surname><given-names>Natsuko</given-names></name><name><surname>Kure</surname><given-names>Shigeo</given-names></name><name><surname>Saitoh</surname><given-names>Shinji</given-names></name></person-group><article-title>Molecular Genetic Dissection and Neonatal/Infantile Intrahepatic Cholestasis Using Targeted Next-Generation Sequencing</article-title><source>The Journal of Pediatrics</source><year>2016</year><volume>171</volume><fpage>171-177.e4</fpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2016.01.006</pub-id><pub-id pub-id-type="pmid">26858187</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Steeg</surname><given-names>E</given-names></name><name><surname>Stranecky</surname><given-names>V</given-names></name><name><surname>Hartmannova</surname><given-names>H</given-names></name><name><surname>Noskova</surname><given-names>L</given-names></name><name><surname>Hrebicek</surname><given-names>M</given-names></name><name><surname>Wagenaar</surname><given-names>E</given-names></name><name><surname>van Esch</surname><given-names>A</given-names></name><etal/></person-group><article-title>Complete OATP1B1 and OATP1B3 deficiency causes human rotor syndrome by interrupting conjugated bilirubin reuptake into the liver</article-title><source>J Clin Invest</source><year>2012</year><volume>122</volume><fpage>519</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1172/JCI59526</pub-id><?supplied-pmid 22232210?><pub-id pub-id-type="pmid">22232210</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kagawa</surname><given-names>T</given-names></name><name><surname>Oka</surname><given-names>A</given-names></name><name><surname>Kobayashi</surname><given-names>Y</given-names></name><name><surname>Hiasa</surname><given-names>Y</given-names></name><name><surname>Kitamura</surname><given-names>T</given-names></name><name><surname>Sakugawa</surname><given-names>H</given-names></name><name><surname>Adachi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Recessive inheritance of population-specific intronic LINE-1 insertion causes a rotor syndrome phenotype</article-title><source>Hum Mutat</source><year>2015</year><volume>36</volume><fpage>327</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1002/humu.22745</pub-id><?supplied-pmid 25546334?><pub-id pub-id-type="pmid">25546334</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dixon</surname><given-names>PH</given-names></name><name><surname>Sambrotta</surname><given-names>M</given-names></name><name><surname>Chambers</surname><given-names>J</given-names></name><name><surname>Taylor-Harris</surname><given-names>P</given-names></name><name><surname>Syngelaki</surname><given-names>A</given-names></name><name><surname>Nicolaides</surname><given-names>K</given-names></name><name><surname>Knisely</surname><given-names>AS</given-names></name><etal/></person-group><article-title>An expanded role for heterozygous mutations of ABCB4, ABCB11, ATP8B1, ABCC2 and TJP2 in intrahepatic cholestasis of pregnancy</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>11823</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-11626-x</pub-id><?supplied-pmid 28924228?><pub-id pub-id-type="pmid">28924228</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Mil</surname><given-names>SW</given-names></name><name><surname>van der Woerd</surname><given-names>WL</given-names></name><name><surname>van der Brugge</surname><given-names>G</given-names></name><name><surname>Sturm</surname><given-names>E</given-names></name><name><surname>Jansen</surname><given-names>PL</given-names></name><name><surname>Bull</surname><given-names>LN</given-names></name><name><surname>van den Berg</surname><given-names>IE</given-names></name><etal/></person-group><article-title>Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11</article-title><source>Gastroenterology</source><year>2004</year><volume>127</volume><fpage>379</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2004.04.065</pub-id><?supplied-pmid 15300568?><pub-id pub-id-type="pmid">15300568</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mullenbach</surname><given-names>R</given-names></name><name><surname>Bennett</surname><given-names>A</given-names></name><name><surname>Tetlow</surname><given-names>N</given-names></name><name><surname>Patel</surname><given-names>N</given-names></name><name><surname>Hamilton</surname><given-names>G</given-names></name><name><surname>Cheng</surname><given-names>F</given-names></name><name><surname>Chambers</surname><given-names>J</given-names></name><etal/></person-group><article-title>ATP8B1 mutations in British cases with intrahepatic cholestasis of pregnancy</article-title><source>Gut</source><year>2005</year><volume>54</volume><fpage>829</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.1136/gut.2004.058115</pub-id><?supplied-pmid 15888793?><pub-id pub-id-type="pmid">15888793</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kagawa</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>N</given-names></name><name><surname>Mochizuki</surname><given-names>K</given-names></name><name><surname>Numari</surname><given-names>A</given-names></name><name><surname>Ikeno</surname><given-names>Y</given-names></name><name><surname>Itoh</surname><given-names>J</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><etal/></person-group><article-title>Phenotypic differences in PFIC2 and BRIC2 correlate with protein stability of mutant Bsep and impaired taurocholate secretion in MDCK II cells</article-title><source>Am J Physiol Gastrointest Liver Physiol</source><year>2008</year><volume>294</volume><fpage>G58</fpage><lpage>G67</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00367.2007</pub-id><?supplied-pmid 17947449?><pub-id pub-id-type="pmid">17947449</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stapelbroek</surname><given-names>JM</given-names></name><name><surname>van Erpecum</surname><given-names>KJ</given-names></name><name><surname>Klomp</surname><given-names>LW</given-names></name><name><surname>Venneman</surname><given-names>NG</given-names></name><name><surname>Schwartz</surname><given-names>TP</given-names></name><name><surname>van Berge Henegouwen</surname><given-names>GP</given-names></name><name><surname>Devlin</surname><given-names>J</given-names></name><etal/></person-group><article-title>Nasobiliary drainage induces long-lasting remission in benign recurrent intrahepatic cholestasis</article-title><source>Hepatology</source><year>2006</year><volume>43</volume><fpage>51</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1002/hep.20998</pub-id><?supplied-pmid 16374853?><pub-id pub-id-type="pmid">16374853</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ulzurrun</surname><given-names>E</given-names></name><name><surname>Stephens</surname><given-names>C</given-names></name><name><surname>Crespo</surname><given-names>E</given-names></name><name><surname>Ruiz-Cabello</surname><given-names>F</given-names></name><name><surname>Ruiz-Nunez</surname><given-names>J</given-names></name><name><surname>Saenz-Lopez</surname><given-names>P</given-names></name><name><surname>Moreno-Herrera</surname><given-names>I</given-names></name><etal/></person-group><article-title>Role of chemical structures and the 1331T&gt;C bile salt export pump polymorphism in idiosyncratic drug-induced liver injury</article-title><source>Liver Int</source><year>2013</year><volume>33</volume><fpage>1378</fpage><lpage>1385</lpage><pub-id pub-id-type="doi">10.1111/liv.12193</pub-id><?supplied-pmid 23701583?><pub-id pub-id-type="pmid">23701583</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kubitz</surname><given-names>R</given-names></name><name><surname>Droge</surname><given-names>C</given-names></name><name><surname>Stindt</surname><given-names>J</given-names></name><name><surname>Weissenberger</surname><given-names>K</given-names></name><name><surname>Haussinger</surname><given-names>D</given-names></name></person-group><article-title>The bile salt export pump (BSEP) in health and disease</article-title><source>Clin Res Hepatol Gastroenterol</source><year>2012</year><volume>36</volume><fpage>536</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1016/j.clinre.2012.06.006</pub-id><?supplied-pmid 22795478?><pub-id pub-id-type="pmid">22795478</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alagille</surname><given-names>D</given-names></name><name><surname>Odievre</surname><given-names>M</given-names></name><name><surname>Gautier</surname><given-names>M</given-names></name><name><surname>Dommergues</surname><given-names>JP</given-names></name></person-group><article-title>Hepatic ductular hypoplasia associated with characteristic facies, vertebral malformations, retarded physical, mental, and sexual development, and cardiac murmur</article-title><source>J Pediatr</source><year>1975</year><volume>86</volume><fpage>63</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/S0022-3476(75)80706-2</pub-id><?supplied-pmid 803282?><pub-id pub-id-type="pmid">803282</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grochowski</surname><given-names>CM</given-names></name><name><surname>Loomes</surname><given-names>KM</given-names></name><name><surname>Spinner</surname><given-names>NB</given-names></name></person-group><article-title>Jagged1 (JAG1): structure, expression, and disease associations</article-title><source>Gene</source><year>2016</year><volume>576</volume><fpage>381</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1016/j.gene.2015.10.065</pub-id><?supplied-pmid 26548814?><pub-id pub-id-type="pmid">26548814</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Bang Lu</surname><given-names>Y</given-names></name><name><surname>Xian Li</surname><given-names>M</given-names></name><name><surname>Nishi</surname><given-names>I</given-names></name><name><surname>Hsiao</surname><given-names>KJ</given-names></name><name><surname>Choeh</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Screening of nine SLC25A13 mutations: their frequency in patients with citrin deficiency and high carrier rates in Asian populations</article-title><source>Mol Genet Metab</source><year>2003</year><volume>80</volume><fpage>356</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1016/S1096-7192(03)00140-9</pub-id><?supplied-pmid 14680984?><pub-id pub-id-type="pmid">14680984</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohura</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Tazawa</surname><given-names>Y</given-names></name><name><surname>Abukawa</surname><given-names>D</given-names></name><name><surname>Sakamoto</surname><given-names>O</given-names></name><name><surname>Tsuchiya</surname><given-names>S</given-names></name><name><surname>Saheki</surname><given-names>T</given-names></name></person-group><article-title>Clinical pictures of 75 patients with neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD)</article-title><source>J Inherit Metab Dis</source><year>2007</year><volume>30</volume><fpage>139</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1007/s10545-007-0506-1</pub-id><?supplied-pmid 17323144?><pub-id pub-id-type="pmid">17323144</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>ST</given-names></name><name><surname>Su</surname><given-names>YN</given-names></name><name><surname>Ni</surname><given-names>YH</given-names></name><name><surname>Hwu</surname><given-names>WL</given-names></name><name><surname>Lee</surname><given-names>NC</given-names></name><name><surname>Chien</surname><given-names>YH</given-names></name><name><surname>Chang</surname><given-names>CC</given-names></name><etal/></person-group><article-title>Diagnosis of neonatal intrahepatic cholestasis caused by citrin deficiency using high-resolution melting analysis and a clinical scoring system</article-title><source>J Pediatr</source><year>2012</year><volume>161</volume><fpage>626</fpage><lpage>631.e622</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2012.03.038</pub-id><?supplied-pmid 22575253?><pub-id pub-id-type="pmid">22575253</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>HW</given-names></name><name><surname>Chen</surname><given-names>HL</given-names></name><name><surname>Ni</surname><given-names>YH</given-names></name><name><surname>Lee</surname><given-names>NC</given-names></name><name><surname>Chien</surname><given-names>YH</given-names></name><name><surname>Hwu</surname><given-names>WL</given-names></name><name><surname>Huang</surname><given-names>YT</given-names></name><etal/></person-group><article-title>Chubby face and the biochemical parameters for the early diagnosis of neonatal intrahepatic cholestasis caused by citrin deficiency</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2008</year><volume>47</volume><fpage>187</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1097/MPG.0b013e318162d96d</pub-id><?supplied-pmid 18664871?><pub-id pub-id-type="pmid">18664871</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clayton</surname><given-names>PT</given-names></name></person-group><article-title>Disorders of bile acid synthesis</article-title><source>J Inherit Metab Dis</source><year>2011</year><volume>34</volume><fpage>593</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1007/s10545-010-9259-3</pub-id><?supplied-pmid 21229319?><pub-id pub-id-type="pmid">21229319</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heubi</surname><given-names>JE</given-names></name><name><surname>Setchell</surname><given-names>KD</given-names></name><name><surname>Jha</surname><given-names>P</given-names></name><name><surname>Buckley</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Rosenthal</surname><given-names>P</given-names></name><name><surname>Potter</surname><given-names>C</given-names></name><etal/></person-group><article-title>Treatment of bile acid amidation defects with glycocholic acid</article-title><source>Hepatology</source><year>2015</year><volume>61</volume><fpage>268</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1002/hep.27401</pub-id><?supplied-pmid 25163551?><pub-id pub-id-type="pmid">25163551</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>Sarah A.</given-names></name><name><surname>Kelly</surname><given-names>Susan</given-names></name><name><surname>Alonso</surname><given-names>Estella M.</given-names></name><name><surname>Whitington</surname><given-names>Peter F.</given-names></name></person-group><article-title>The Effects of Gestational Alloimmune Liver Disease on Fetal and Infant Morbidity and Mortality</article-title><source>The Journal of Pediatrics</source><year>2018</year><volume>196</volume><fpage>123-128.e1</fpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2017.12.054</pub-id><?supplied-pmid 29499991?><pub-id pub-id-type="pmid">29499991</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>FT</given-names></name><name><surname>Wu</surname><given-names>JF</given-names></name><name><surname>Hsu</surname><given-names>HY</given-names></name><name><surname>Ni</surname><given-names>YH</given-names></name><name><surname>Chang</surname><given-names>MH</given-names></name><name><surname>Chao</surname><given-names>CI</given-names></name><name><surname>Chen</surname><given-names>HL</given-names></name></person-group><article-title>Gamma-Glutamyl transpeptidase level as a screening marker among diverse etiologies of infantile intrahepatic cholestasis</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2014</year><volume>59</volume><fpage>695</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1097/MPG.0000000000000538</pub-id><?supplied-pmid 25141230?><pub-id pub-id-type="pmid">25141230</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pawlikowska</surname><given-names>L</given-names></name><name><surname>Strautnieks</surname><given-names>S</given-names></name><name><surname>Jankowska</surname><given-names>I</given-names></name><name><surname>Czubkowski</surname><given-names>P</given-names></name><name><surname>Emerick</surname><given-names>K</given-names></name><name><surname>Antoniou</surname><given-names>A</given-names></name><name><surname>Wanty</surname><given-names>C</given-names></name><etal/></person-group><article-title>Differences in presentation and progression between severe FIC1 and BSEP deficiencies</article-title><source>J Hepatol</source><year>2010</year><volume>53</volume><fpage>170</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2010.01.034</pub-id><?supplied-pmid 20447715?><pub-id pub-id-type="pmid">20447715</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saheki</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name></person-group><article-title>Mitochondrial aspartate glutamate carrier (citrin) deficiency as the cause of adult-onset type II citrullinemia (CTLN2) and idiopathic neonatal hepatitis (NICCD)</article-title><source>J Hum Genet</source><year>2002</year><volume>47</volume><fpage>333</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1007/s100380200046</pub-id><?supplied-pmid 12111366?><pub-id pub-id-type="pmid">12111366</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heubi</surname><given-names>JE</given-names></name><name><surname>Setchell</surname><given-names>KD</given-names></name><name><surname>Bove</surname><given-names>KE</given-names></name></person-group><article-title>Inborn errors of bile acid metabolism</article-title><source>Semin Liver Dis</source><year>2007</year><volume>27</volume><fpage>282</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1055/s-2007-985073</pub-id><?supplied-pmid 17682975?><pub-id pub-id-type="pmid">17682975</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Aronow</surname><given-names>BJ</given-names></name><name><surname>Jegga</surname><given-names>AG</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Miethke</surname><given-names>A</given-names></name><name><surname>Mourya</surname><given-names>R</given-names></name><name><surname>Bezerra</surname><given-names>JA</given-names></name></person-group><article-title>Novel resequencing chip customized to diagnose mutations in patients with inherited syndromes of intrahepatic cholestasis</article-title><source>Gastroenterology</source><year>2007</year><volume>132</volume><fpage>119</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2006.10.034</pub-id><?supplied-pmid 17241866?><pub-id pub-id-type="pmid">17241866</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vitale</surname><given-names>G</given-names></name><name><surname>Pirillo</surname><given-names>M</given-names></name><name><surname>Mantovani</surname><given-names>V</given-names></name><name><surname>Marasco</surname><given-names>E</given-names></name><name><surname>Aquilano</surname><given-names>A</given-names></name><name><surname>Gamal</surname><given-names>N</given-names></name><name><surname>Francalanci</surname><given-names>P</given-names></name><etal/></person-group><article-title>Bile salt export pump deficiency disease: two novel, late onset, ABCB11 mutations identified by next generation sequencing</article-title><source>Ann Hepatol</source><year>2016</year><volume>15</volume><fpage>795</fpage><lpage>800</lpage><?supplied-pmid 27493120?><pub-id pub-id-type="pmid">27493120</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><mixed-citation publication-type="other">Karpen SJ, Kamath BM, Alexander II, Ichetovkin I, Rosenthal P, Soliman W, ea. Use of a comprehensive 66 gene panel to diagnosis the cause of cholestasis in &gt; 700 individuals. Hepatology 2017; 66(suppl 1):655A. [AASLD abstract].</mixed-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paumgartner</surname><given-names>G</given-names></name><name><surname>Beuers</surname><given-names>U</given-names></name></person-group><article-title>Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited</article-title><source>Hepatology</source><year>2002</year><volume>36</volume><fpage>525</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1053/jhep.2002.36088</pub-id><pub-id pub-id-type="pmid">12198643</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>HL</given-names></name><name><surname>Chen</surname><given-names>HL</given-names></name><name><surname>Yuan</surname><given-names>RH</given-names></name><name><surname>Wu</surname><given-names>SH</given-names></name><name><surname>Chen</surname><given-names>YH</given-names></name><name><surname>Chien</surname><given-names>CS</given-names></name><name><surname>Chou</surname><given-names>SP</given-names></name><etal/></person-group><article-title>Hepatocyte transplantation in bile salt export pump-deficient mice: selective growth advantage of donor hepatocytes under bile acid stress</article-title><source>J Cell Mol Med</source><year>2012</year><volume>16</volume><fpage>2679</fpage><lpage>2689</lpage><pub-id pub-id-type="doi">10.1111/j.1582-4934.2012.01586.x</pub-id><?supplied-pmid 22564513?><pub-id pub-id-type="pmid">22564513</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>H</given-names></name><name><surname>Sugiyama</surname><given-names>Y</given-names></name></person-group><article-title>4-phenylbutyrate enhances the cell surface expression and the transport capacity of wild-type and mutated bile salt export pumps</article-title><source>Hepatology</source><year>2007</year><volume>45</volume><fpage>1506</fpage><lpage>1516</lpage><pub-id pub-id-type="doi">10.1002/hep.21630</pub-id><?supplied-pmid 17538928?><pub-id pub-id-type="pmid">17538928</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>H</given-names></name><name><surname>Mizuno</surname><given-names>T</given-names></name><name><surname>Horikawa</surname><given-names>R</given-names></name><name><surname>Nagasaka</surname><given-names>H</given-names></name><name><surname>Yabuki</surname><given-names>T</given-names></name><name><surname>Takikawa</surname><given-names>H</given-names></name><name><surname>Sugiyama</surname><given-names>Y</given-names></name></person-group><article-title>4-Phenylbutyrate modulates ubiquitination of hepatocanalicular MRP2 and reduces serum total bilirubin concentration</article-title><source>J Hepatol</source><year>2012</year><volume>56</volume><fpage>1136</fpage><lpage>1144</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2011.11.021</pub-id><?supplied-pmid 22245901?><pub-id pub-id-type="pmid">22245901</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzales</surname><given-names>E</given-names></name><name><surname>Grosse</surname><given-names>B</given-names></name><name><surname>Cassio</surname><given-names>D</given-names></name><name><surname>Davit-Spraul</surname><given-names>A</given-names></name><name><surname>Fabre</surname><given-names>M</given-names></name><name><surname>Jacquemin</surname><given-names>E</given-names></name></person-group><article-title>Successful mutation-specific chaperone therapy with 4-phenylbutyrate in a child with progressive familial intrahepatic cholestasis type 2</article-title><source>J Hepatol</source><year>2012</year><volume>57</volume><fpage>695</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2012.04.017</pub-id><?supplied-pmid 22609309?><pub-id pub-id-type="pmid">22609309</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kubitz</surname><given-names>R</given-names></name><name><surname>Warskulat</surname><given-names>U</given-names></name><name><surname>Schmitt</surname><given-names>M</given-names></name><name><surname>Haussinger</surname><given-names>D</given-names></name></person-group><article-title>Dexamethasone- and osmolarity-dependent expression of the multidrug-resistance protein 2 in cultured rat hepatocytes</article-title><source>Biochem J</source><year>1999</year><volume>340</volume><issue>Pt 3</issue><fpage>585</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1042/bj3400585</pub-id><?supplied-pmid 10359641?><pub-id pub-id-type="pmid">10359641</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warskulat</surname><given-names>U</given-names></name><name><surname>Kubitz</surname><given-names>R</given-names></name><name><surname>Wettstein</surname><given-names>M</given-names></name><name><surname>Stieger</surname><given-names>B</given-names></name><name><surname>Meier</surname><given-names>PJ</given-names></name><name><surname>Haussinger</surname><given-names>D</given-names></name></person-group><article-title>Regulation of bile salt export pump mRNA levels by dexamethasone and osmolarity in cultured rat hepatocytes</article-title><source>Biol Chem</source><year>1999</year><volume>380</volume><fpage>1273</fpage><lpage>1279</lpage><pub-id pub-id-type="doi">10.1515/BC.1999.162</pub-id><?supplied-pmid 10614819?><pub-id pub-id-type="pmid">10614819</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fardel</surname><given-names>O</given-names></name><name><surname>Payen</surname><given-names>L</given-names></name><name><surname>Courtois</surname><given-names>A</given-names></name><name><surname>Vernhet</surname><given-names>L</given-names></name><name><surname>Lecureur</surname><given-names>V</given-names></name></person-group><article-title>Regulation of biliary drug efflux pump expression by hormones and xenobiotics</article-title><source>Toxicology</source><year>2001</year><volume>167</volume><fpage>37</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/S0300-483X(01)00456-5</pub-id><?supplied-pmid 11557128?><pub-id pub-id-type="pmid">11557128</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brems</surname><given-names>JJ</given-names></name><name><surname>Reese</surname><given-names>J</given-names></name><name><surname>Kane</surname><given-names>R</given-names><suffix>3rd</suffix></name><name><surname>Kaminski</surname><given-names>DL</given-names></name></person-group><article-title>Effect of cyclosporine and steroids on canine bile flow</article-title><source>Hepatology</source><year>1991</year><volume>14</volume><fpage>523</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1002/hep.1840140319</pub-id><?supplied-pmid 1874497?><pub-id pub-id-type="pmid">1874497</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engelmann</surname><given-names>G</given-names></name><name><surname>Wenning</surname><given-names>D</given-names></name><name><surname>Herebian</surname><given-names>D</given-names></name><name><surname>Sander</surname><given-names>O</given-names></name><name><surname>Droge</surname><given-names>C</given-names></name><name><surname>Kluge</surname><given-names>S</given-names></name><name><surname>Kubitz</surname><given-names>R</given-names></name></person-group><article-title>Two case reports of successful treatment of cholestasis with steroids in patients with PFIC-2</article-title><source>Pediatrics</source><year>2015</year><volume>135</volume><fpage>e1326</fpage><lpage>e1332</lpage><pub-id pub-id-type="doi">10.1542/peds.2014-2376</pub-id><?supplied-pmid 25847799?><pub-id pub-id-type="pmid">25847799</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miethke</surname><given-names>AG</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Simmons</surname><given-names>J</given-names></name><name><surname>Taylor</surname><given-names>AE</given-names></name><name><surname>Shi</surname><given-names>T</given-names></name><name><surname>Shanmukhappa</surname><given-names>SK</given-names></name><name><surname>Karns</surname><given-names>R</given-names></name><etal/></person-group><article-title>Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice</article-title><source>Hepatology</source><year>2016</year><volume>63</volume><fpage>512</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1002/hep.27973</pub-id><?supplied-pmid 26172874?><pub-id pub-id-type="pmid">26172874</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirschfield</surname><given-names>GM</given-names></name><name><surname>Mason</surname><given-names>A</given-names></name><name><surname>Luketic</surname><given-names>V</given-names></name><name><surname>Lindor</surname><given-names>K</given-names></name><name><surname>Gordon</surname><given-names>SC</given-names></name><name><surname>Mayo</surname><given-names>M</given-names></name><name><surname>Kowdley</surname><given-names>KV</given-names></name><etal/></person-group><article-title>Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid</article-title><source>Gastroenterology</source><year>2015</year><volume>148</volume><fpage>751</fpage><lpage>761.e758</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2014.12.005</pub-id><?supplied-pmid 25500425?><pub-id pub-id-type="pmid">25500425</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mudaliar</surname><given-names>S</given-names></name><name><surname>Henry</surname><given-names>RR</given-names></name><name><surname>Sanyal</surname><given-names>AJ</given-names></name><name><surname>Morrow</surname><given-names>L</given-names></name><name><surname>Marschall</surname><given-names>HU</given-names></name><name><surname>Kipnes</surname><given-names>M</given-names></name><name><surname>Adorini</surname><given-names>L</given-names></name><etal/></person-group><article-title>Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease</article-title><source>Gastroenterology</source><year>2013</year><volume>145</volume><fpage>574</fpage><lpage>582.e571</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2013.05.042</pub-id><?supplied-pmid 23727264?><pub-id pub-id-type="pmid">23727264</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neuschwander-Tetri</surname><given-names>BA</given-names></name><name><surname>Loomba</surname><given-names>R</given-names></name><name><surname>Sanyal</surname><given-names>AJ</given-names></name><name><surname>Lavine</surname><given-names>JE</given-names></name><name><surname>Van Natta</surname><given-names>ML</given-names></name><name><surname>Abdelmalek</surname><given-names>MF</given-names></name><name><surname>Chalasani</surname><given-names>N</given-names></name><etal/></person-group><article-title>Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial</article-title><source>Lancet</source><year>2015</year><volume>385</volume><fpage>956</fpage><lpage>965</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(14)61933-4</pub-id><pub-id pub-id-type="pmid">25468160</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beuers</surname><given-names>U</given-names></name><name><surname>Trauner</surname><given-names>M</given-names></name><name><surname>Jansen</surname><given-names>P</given-names></name><name><surname>Poupon</surname><given-names>R</given-names></name></person-group><article-title>New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond</article-title><source>J Hepatol</source><year>2015</year><volume>62</volume><fpage>S25</fpage><lpage>S37</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2015.02.023</pub-id><?supplied-pmid 25920087?><pub-id pub-id-type="pmid">25920087</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heubi</surname><given-names>JE</given-names></name><name><surname>Bove</surname><given-names>KE</given-names></name><name><surname>Setchell</surname><given-names>KDR</given-names></name></person-group><article-title>Oral Cholic acid is efficacious and well tolerated in patients with bile acid synthesis and Zellweger Spectrum disorders</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2017</year><volume>65</volume><fpage>321</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1097/MPG.0000000000001657</pub-id><?supplied-pmid 28644367?><pub-id pub-id-type="pmid">28644367</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>D</given-names></name><name><surname>Mills</surname><given-names>PB</given-names></name><name><surname>Footitt</surname><given-names>E</given-names></name><name><surname>Gissen</surname><given-names>P</given-names></name><name><surname>McClean</surname><given-names>P</given-names></name><name><surname>Stahlschmidt</surname><given-names>J</given-names></name><name><surname>Coupry</surname><given-names>I</given-names></name><etal/></person-group><article-title>Liver disease in infancy caused by oxysterol 7 alpha-hydroxylase deficiency: successful treatment with chenodeoxycholic acid</article-title><source>J Inherit Metab Dis</source><year>2014</year><volume>37</volume><fpage>851</fpage><lpage>861</lpage><pub-id pub-id-type="doi">10.1007/s10545-014-9695-6</pub-id><?supplied-pmid 24658845?><pub-id pub-id-type="pmid">24658845</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jericho</surname><given-names>HS</given-names></name><name><surname>Kaurs</surname><given-names>E</given-names></name><name><surname>Boverhof</surname><given-names>R</given-names></name><name><surname>Knisely</surname><given-names>A</given-names></name><name><surname>Shneider</surname><given-names>BL</given-names></name><name><surname>Verkade</surname><given-names>HJ</given-names></name><name><surname>Whitington</surname><given-names>PF</given-names></name></person-group><article-title>Bile acid pool dynamics in progressive familial intrahepatic cholestasis with partial external bile diversion</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2015</year><volume>60</volume><fpage>368</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1097/MPG.0000000000000630</pub-id><?supplied-pmid 25383786?><pub-id pub-id-type="pmid">25383786</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emerick</surname><given-names>KM</given-names></name><name><surname>Elias</surname><given-names>MS</given-names></name><name><surname>Melin-Aldana</surname><given-names>H</given-names></name><name><surname>Strautnieks</surname><given-names>S</given-names></name><name><surname>Thompson</surname><given-names>RJ</given-names></name><name><surname>Bull</surname><given-names>LN</given-names></name><name><surname>Knisely</surname><given-names>A</given-names></name><etal/></person-group><article-title>Bile composition in Alagille syndrome and PFIC patients having partial external biliary diversion</article-title><source>BMC Gastroenterol</source><year>2008</year><volume>8</volume><fpage>47</fpage><pub-id pub-id-type="doi">10.1186/1471-230X-8-47</pub-id><?supplied-pmid 18937870?><pub-id pub-id-type="pmid">18937870</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jankowska</surname><given-names>I</given-names></name><name><surname>Czubkowski</surname><given-names>P</given-names></name><name><surname>Kalicinski</surname><given-names>P</given-names></name><name><surname>Ismail</surname><given-names>H</given-names></name><name><surname>Kowalski</surname><given-names>A</given-names></name><name><surname>Ryzko</surname><given-names>J</given-names></name><name><surname>Pawlowska</surname><given-names>J</given-names></name></person-group><article-title>Ileal exclusion in children with progressive familial intrahepatic cholestasis</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2014</year><volume>58</volume><fpage>92</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1097/MPG.0b013e3182a9097c</pub-id><?supplied-pmid 24385022?><pub-id pub-id-type="pmid">24385022</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oishi</surname><given-names>K</given-names></name><name><surname>Arnon</surname><given-names>R</given-names></name><name><surname>Wasserstein</surname><given-names>MP</given-names></name><name><surname>Diaz</surname><given-names>GA</given-names></name></person-group><article-title>Liver transplantation for pediatric inherited metabolic disorders: considerations for indications, complications, and perioperative management</article-title><source>Pediatr Transplant</source><year>2016</year><volume>20</volume><fpage>756</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.1111/petr.12741</pub-id><?supplied-pmid 27329540?><pub-id pub-id-type="pmid">27329540</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jara</surname><given-names>P</given-names></name><name><surname>Hierro</surname><given-names>L</given-names></name><name><surname>Martinez-Fernandez</surname><given-names>P</given-names></name><name><surname>Alvarez-Doforno</surname><given-names>R</given-names></name><name><surname>Yanez</surname><given-names>F</given-names></name><name><surname>Diaz</surname><given-names>MC</given-names></name><name><surname>Camarena</surname><given-names>C</given-names></name><etal/></person-group><article-title>Recurrence of bile salt export pump deficiency after liver transplantation</article-title><source>N Engl J Med</source><year>2009</year><volume>361</volume><fpage>1359</fpage><lpage>1367</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0901075</pub-id><?supplied-pmid 19797282?><pub-id pub-id-type="pmid">19797282</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stindt</surname><given-names>J</given-names></name><name><surname>Kluge</surname><given-names>S</given-names></name><name><surname>Droge</surname><given-names>C</given-names></name><name><surname>Keitel</surname><given-names>V</given-names></name><name><surname>Stross</surname><given-names>C</given-names></name><name><surname>Baumann</surname><given-names>U</given-names></name><name><surname>Brinkert</surname><given-names>F</given-names></name><etal/></person-group><article-title>Bile salt export pump-reactive antibodies form a polyclonal, multi-inhibitory response in antibody-induced bile salt export pump deficiency</article-title><source>Hepatology</source><year>2016</year><volume>63</volume><fpage>524</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1002/hep.28311</pub-id><?supplied-pmid 26516723?><pub-id pub-id-type="pmid">26516723</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>HC</given-names></name><name><surname>Alvarez</surname><given-names>L</given-names></name><name><surname>Laroche</surname><given-names>G</given-names></name><name><surname>Melin-Aldana</surname><given-names>H</given-names></name><name><surname>Pfeifer</surname><given-names>K</given-names></name><name><surname>Schwarz</surname><given-names>K</given-names></name><name><surname>Whitington</surname><given-names>PF</given-names></name><etal/></person-group><article-title>Rituximab as therapy for the recurrence of bile salt export pump deficiency after liver transplantation</article-title><source>Liver Transpl</source><year>2013</year><volume>19</volume><fpage>1403</fpage><lpage>1410</lpage><pub-id pub-id-type="doi">10.1002/lt.23754</pub-id><?supplied-pmid 24115678?><pub-id pub-id-type="pmid">24115678</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knisely</surname><given-names>AS</given-names></name><name><surname>Strautnieks</surname><given-names>SS</given-names></name><name><surname>Meier</surname><given-names>Y</given-names></name><name><surname>Stieger</surname><given-names>B</given-names></name><name><surname>Byrne</surname><given-names>JA</given-names></name><name><surname>Portmann</surname><given-names>BC</given-names></name><name><surname>Bull</surname><given-names>LN</given-names></name><etal/></person-group><article-title>Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency</article-title><source>Hepatology</source><year>2006</year><volume>44</volume><fpage>478</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1002/hep.21287</pub-id><?supplied-pmid 16871584?><pub-id pub-id-type="pmid">16871584</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheimann</surname><given-names>AO</given-names></name><name><surname>Strautnieks</surname><given-names>SS</given-names></name><name><surname>Knisely</surname><given-names>AS</given-names></name><name><surname>Byrne</surname><given-names>JA</given-names></name><name><surname>Thompson</surname><given-names>RJ</given-names></name><name><surname>Finegold</surname><given-names>MJ</given-names></name></person-group><article-title>Mutations in bile salt export pump (ABCB11) in two children with progressive familial intrahepatic cholestasis and cholangiocarcinoma</article-title><source>J Pediatr</source><year>2007</year><volume>150</volume><fpage>556</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2007.02.030</pub-id><?supplied-pmid 17452236?><pub-id pub-id-type="pmid">17452236</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baumann</surname><given-names>U</given-names></name><name><surname>Adam</surname><given-names>R</given-names></name><name><surname>Duvoux</surname><given-names>C</given-names></name><name><surname>Mikolajczyk</surname><given-names>R</given-names></name><name><surname>Karam</surname><given-names>V</given-names></name><name><surname>D'Antiga</surname><given-names>L</given-names></name><name><surname>Chardot</surname><given-names>C</given-names></name><etal/></person-group><article-title>Survival of children after liver transplantation for hepatocellular carcinoma</article-title><source>Liver Transpl</source><year>2018</year><volume>24</volume><fpage>246</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1002/lt.24994</pub-id><?supplied-pmid 29222922?><pub-id pub-id-type="pmid">29222922</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>HL</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>HL</given-names></name><name><surname>Hwu</surname><given-names>WL</given-names></name><name><surname>Jeng</surname><given-names>YM</given-names></name><name><surname>Chang</surname><given-names>MH</given-names></name><name><surname>Ling</surname><given-names>V</given-names></name></person-group><article-title>Bone marrow transplantation results in donor-derived hepatocytes in an animal model of inherited cholestatic liver disease</article-title><source>J Biomed Sci</source><year>2008</year><volume>15</volume><fpage>615</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1007/s11373-008-9255-x</pub-id><?supplied-pmid 18509747?><pub-id pub-id-type="pmid">18509747</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>AJ</given-names></name><name><surname>de Vree</surname><given-names>JM</given-names></name><name><surname>Ottenhoff</surname><given-names>R</given-names></name><name><surname>Oude Elferink</surname><given-names>RP</given-names></name><name><surname>Schinkel</surname><given-names>AH</given-names></name><name><surname>Borst</surname><given-names>P</given-names></name></person-group><article-title>Hepatocyte-specific expression of the human MDR3 P-glycoprotein gene restores the biliary phosphatidylcholine excretion absent in Mdr2 (&#8722;/&#8722;) mice</article-title><source>Hepatology</source><year>1998</year><volume>28</volume><fpage>530</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1002/hep.510280234</pub-id><?supplied-pmid 9696021?><pub-id pub-id-type="pmid">9696021</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Overturf</surname><given-names>K</given-names></name><name><surname>Al-Dhalimy</surname><given-names>M</given-names></name><name><surname>Tanguay</surname><given-names>R</given-names></name><name><surname>Brantly</surname><given-names>M</given-names></name><name><surname>Ou</surname><given-names>CN</given-names></name><name><surname>Finegold</surname><given-names>M</given-names></name><name><surname>Grompe</surname><given-names>M</given-names></name></person-group><article-title>Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I</article-title><source>Nat Genet</source><year>1996</year><volume>12</volume><fpage>266</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1038/ng0396-266</pub-id><?supplied-pmid 8589717?><pub-id pub-id-type="pmid">8589717</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sokal</surname><given-names>EM</given-names></name><name><surname>Smets</surname><given-names>F</given-names></name><name><surname>Bourgois</surname><given-names>A</given-names></name><name><surname>Van Maldergem</surname><given-names>L</given-names></name><name><surname>Buts</surname><given-names>JP</given-names></name><name><surname>Reding</surname><given-names>R</given-names></name><name><surname>Bernard Otte</surname><given-names>J</given-names></name><etal/></person-group><article-title>Hepatocyte transplantation in a 4-year-old girl with peroxisomal biogenesis disease: technique, safety, and metabolic follow-up</article-title><source>Transplantation</source><year>2003</year><volume>76</volume><fpage>735</fpage><lpage>738</lpage><pub-id pub-id-type="doi">10.1097/01.TP.0000077420.81365.53</pub-id><?supplied-pmid 12973120?><pub-id pub-id-type="pmid">12973120</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quaglia</surname><given-names>A</given-names></name><name><surname>Lehec</surname><given-names>SC</given-names></name><name><surname>Hughes</surname><given-names>RD</given-names></name><name><surname>Mitry</surname><given-names>RR</given-names></name><name><surname>Knisely</surname><given-names>AS</given-names></name><name><surname>Devereaux</surname><given-names>S</given-names></name><name><surname>Richards</surname><given-names>J</given-names></name><etal/></person-group><article-title>Liver after hepatocyte transplantation for liver-based metabolic disorders in children</article-title><source>Cell Transplant</source><year>2008</year><volume>17</volume><fpage>1403</fpage><lpage>1414</lpage><pub-id pub-id-type="doi">10.3727/096368908787648083</pub-id><?supplied-pmid 19364077?><pub-id pub-id-type="pmid">19364077</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heath</surname><given-names>RD</given-names></name><name><surname>Ertem</surname><given-names>F</given-names></name><name><surname>Romana</surname><given-names>BS</given-names></name><name><surname>Ibdah</surname><given-names>JA</given-names></name><name><surname>Tahan</surname><given-names>V</given-names></name></person-group><article-title>Hepatocyte transplantation: consider infusion before incision</article-title><source>World J Transplant</source><year>2017</year><volume>7</volume><fpage>317</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.5500/wjt.v7.i6.317</pub-id><?supplied-pmid 29312860?><pub-id pub-id-type="pmid">29312860</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boudechiche</surname><given-names>L</given-names></name><name><surname>Tranchart</surname><given-names>H</given-names></name><name><surname>Branchereau</surname><given-names>S</given-names></name><name><surname>Davit-Spraul</surname><given-names>A</given-names></name><name><surname>Lainas</surname><given-names>P</given-names></name><name><surname>Groyer-Picard</surname><given-names>MT</given-names></name><name><surname>Weber</surname><given-names>A</given-names></name><etal/></person-group><article-title>Improvement of hepatocyte transplantation efficiency in the mdr2&#8722;/&#8722; mouse model by glyceryl trinitrate</article-title><source>Transplantation</source><year>2015</year><volume>99</volume><fpage>36</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1097/TP.0000000000000463</pub-id><?supplied-pmid 25340599?><pub-id pub-id-type="pmid">25340599</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marrone</surname><given-names>J</given-names></name><name><surname>Lehmann</surname><given-names>GL</given-names></name><name><surname>Soria</surname><given-names>LR</given-names></name><name><surname>Pellegrino</surname><given-names>JM</given-names></name><name><surname>Molinas</surname><given-names>S</given-names></name><name><surname>Marinelli</surname><given-names>RA</given-names></name></person-group><article-title>Adenoviral transfer of human aquaporin-1 gene to rat liver improves bile flow in estrogen-induced cholestasis</article-title><source>Gene Ther</source><year>2014</year><volume>21</volume><fpage>1058</fpage><lpage>1064</lpage><pub-id pub-id-type="doi">10.1038/gt.2014.78</pub-id><?supplied-pmid 25208977?><pub-id pub-id-type="pmid">25208977</pub-id></element-citation></ref></ref-list></back></article>